Companies: 10,762     total market cap: $132.625 T
โ‚ฌEUR๐Ÿ‡ช๐Ÿ‡บโ‚นINR๐Ÿ‡ฎ๐Ÿ‡ณยฃGBP๐Ÿ‡ฌ๐Ÿ‡ง$CAD๐Ÿ‡จ๐Ÿ‡ฆ$AUD๐Ÿ‡ฆ๐Ÿ‡บ$NZD๐Ÿ‡ณ๐Ÿ‡ฟ$HKD๐Ÿ‡ญ๐Ÿ‡ฐ$SGD๐Ÿ‡ธ๐Ÿ‡ฌ
The Joint Corp.
JYNT
#9018
Rank
$0.13 B
Marketcap
๐Ÿ‡บ๐Ÿ‡ธ United States
Country
$8.85
Share price
3.51%
Change (1 day)
-29.14%
Change (1 year)
  1. The Joint Corp.
  2. Quarterly Reports (10-Q)
  3. Financial Year FY2023 Q2

The Joint Corp. - 10-Q quarterly report FY2023 Q2


Text size:
000161263012-312023Q2falseP3YP6MP1YP1YP1YP1YP6YP4YP5Y00016126302023-01-012023-06-3000016126302023-09-11xbrli:shares00016126302023-06-30iso4217:USD00016126302022-12-310001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-06-300001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-31iso4217:USDxbrli:shares0001612630jynt:RevenuesAndManagementFeesFromCompanyClinicsMember2023-04-012023-06-300001612630jynt:RevenuesAndManagementFeesFromCompanyClinicsMember2022-04-012022-06-300001612630jynt:RevenuesAndManagementFeesFromCompanyClinicsMember2023-01-012023-06-300001612630jynt:RevenuesAndManagementFeesFromCompanyClinicsMember2022-01-012022-06-300001612630us-gaap:RoyaltyMember2023-04-012023-06-300001612630us-gaap:RoyaltyMember2022-04-012022-06-300001612630us-gaap:RoyaltyMember2023-01-012023-06-300001612630us-gaap:RoyaltyMember2022-01-012022-06-300001612630us-gaap:FranchiseMember2023-04-012023-06-300001612630us-gaap:FranchiseMember2022-04-012022-06-300001612630us-gaap:FranchiseMember2023-01-012023-06-300001612630us-gaap:FranchiseMember2022-01-012022-06-300001612630us-gaap:AdvertisingMember2023-04-012023-06-300001612630us-gaap:AdvertisingMember2022-04-012022-06-300001612630us-gaap:AdvertisingMember2023-01-012023-06-300001612630us-gaap:AdvertisingMember2022-01-012022-06-300001612630us-gaap:TechnologyServiceMember2023-04-012023-06-300001612630us-gaap:TechnologyServiceMember2022-04-012022-06-300001612630us-gaap:TechnologyServiceMember2023-01-012023-06-300001612630us-gaap:TechnologyServiceMember2022-01-012022-06-300001612630jynt:RegionalDeveloperFeesMember2023-04-012023-06-300001612630jynt:RegionalDeveloperFeesMember2022-04-012022-06-300001612630jynt:RegionalDeveloperFeesMember2023-01-012023-06-300001612630jynt:RegionalDeveloperFeesMember2022-01-012022-06-300001612630us-gaap:ProductAndServiceOtherMember2023-04-012023-06-300001612630us-gaap:ProductAndServiceOtherMember2022-04-012022-06-300001612630us-gaap:ProductAndServiceOtherMember2023-01-012023-06-300001612630us-gaap:ProductAndServiceOtherMember2022-01-012022-06-3000016126302023-04-012023-06-3000016126302022-04-012022-06-3000016126302022-01-012022-06-300001612630us-gaap:CommonStockMember2022-12-310001612630us-gaap:AdditionalPaidInCapitalMember2022-12-310001612630us-gaap:TreasuryStockCommonMember2022-12-310001612630us-gaap:RetainedEarningsMember2022-12-310001612630us-gaap:ParentMember2022-12-310001612630us-gaap:NoncontrollingInterestMember2022-12-310001612630us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001612630us-gaap:ParentMember2023-01-012023-03-3100016126302023-01-012023-03-310001612630us-gaap:CommonStockMember2023-01-012023-03-310001612630us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001612630us-gaap:RetainedEarningsMember2023-01-012023-03-310001612630us-gaap:CommonStockMember2023-03-310001612630us-gaap:AdditionalPaidInCapitalMember2023-03-310001612630us-gaap:TreasuryStockCommonMember2023-03-310001612630us-gaap:RetainedEarningsMember2023-03-310001612630us-gaap:ParentMember2023-03-310001612630us-gaap:NoncontrollingInterestMember2023-03-3100016126302023-03-310001612630us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001612630us-gaap:ParentMember2023-04-012023-06-300001612630us-gaap:CommonStockMember2023-04-012023-06-300001612630us-gaap:RetainedEarningsMember2023-04-012023-06-300001612630us-gaap:CommonStockMember2023-06-300001612630us-gaap:AdditionalPaidInCapitalMember2023-06-300001612630us-gaap:TreasuryStockCommonMember2023-06-300001612630us-gaap:RetainedEarningsMember2023-06-300001612630us-gaap:ParentMember2023-06-300001612630us-gaap:NoncontrollingInterestMember2023-06-300001612630us-gaap:CommonStockMember2021-12-310001612630us-gaap:AdditionalPaidInCapitalMember2021-12-310001612630us-gaap:TreasuryStockCommonMember2021-12-310001612630us-gaap:RetainedEarningsMember2021-12-310001612630us-gaap:ParentMember2021-12-310001612630us-gaap:NoncontrollingInterestMember2021-12-3100016126302021-12-310001612630us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001612630us-gaap:ParentMember2022-01-012022-03-3100016126302022-01-012022-03-310001612630us-gaap:CommonStockMember2022-01-012022-03-310001612630us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001612630us-gaap:RetainedEarningsMember2022-01-012022-03-310001612630us-gaap:CommonStockMember2022-03-310001612630us-gaap:AdditionalPaidInCapitalMember2022-03-310001612630us-gaap:TreasuryStockCommonMember2022-03-310001612630us-gaap:RetainedEarningsMember2022-03-310001612630us-gaap:ParentMember2022-03-310001612630us-gaap:NoncontrollingInterestMember2022-03-3100016126302022-03-310001612630us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001612630us-gaap:ParentMember2022-04-012022-06-300001612630us-gaap:CommonStockMember2022-04-012022-06-300001612630us-gaap:RetainedEarningsMember2022-04-012022-06-300001612630us-gaap:CommonStockMember2022-06-300001612630us-gaap:AdditionalPaidInCapitalMember2022-06-300001612630us-gaap:TreasuryStockCommonMember2022-06-300001612630us-gaap:RetainedEarningsMember2022-06-300001612630us-gaap:ParentMember2022-06-300001612630us-gaap:NoncontrollingInterestMember2022-06-3000016126302022-06-300001612630jynt:AZClinicsMember2023-01-012023-06-300001612630jynt:AZClinicsMember2022-01-012022-06-300001612630jynt:CAClinicsMember2023-01-012023-06-300001612630jynt:CAClinicsMember2022-01-012022-06-300001612630jynt:FranchiseFeesCollectedUponFranchiseAgreementMember2023-06-300001612630jynt:FranchiseFeesCollectedUponFranchiseAgreementMember2022-06-300001612630srt:ScenarioPreviouslyReportedMember2022-06-300001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-06-300001612630srt:ScenarioPreviouslyReportedMemberjynt:RegionalDeveloperFeesMember2022-04-012022-06-300001612630srt:ScenarioPreviouslyReportedMemberjynt:RegionalDeveloperFeesMember2022-01-012022-06-300001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberjynt:RegionalDeveloperFeesMember2022-04-012022-06-300001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberjynt:RegionalDeveloperFeesMember2022-01-012022-06-300001612630srt:ScenarioPreviouslyReportedMember2022-04-012022-06-300001612630srt:ScenarioPreviouslyReportedMember2022-01-012022-06-300001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-04-012022-06-300001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-06-300001612630srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2021-12-310001612630srt:ScenarioPreviouslyReportedMemberus-gaap:ParentMember2021-12-310001612630srt:ScenarioPreviouslyReportedMember2021-12-310001612630us-gaap:RetainedEarningsMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-12-310001612630us-gaap:ParentMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-12-310001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-12-310001612630srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2022-03-310001612630srt:ScenarioPreviouslyReportedMemberus-gaap:ParentMember2022-03-310001612630srt:ScenarioPreviouslyReportedMember2022-03-310001612630us-gaap:RetainedEarningsMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-03-310001612630us-gaap:ParentMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-03-310001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-03-310001612630srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2022-06-300001612630srt:ScenarioPreviouslyReportedMemberus-gaap:ParentMember2022-06-300001612630us-gaap:RetainedEarningsMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-06-300001612630us-gaap:ParentMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-06-300001612630srt:ScenarioPreviouslyReportedMember2023-03-310001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-03-310001612630srt:ScenarioPreviouslyReportedMemberjynt:RegionalDeveloperFeesMember2023-01-012023-03-310001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberjynt:RegionalDeveloperFeesMember2023-01-012023-03-310001612630jynt:RegionalDeveloperFeesMember2023-01-012023-03-310001612630srt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001612630srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001612630us-gaap:FranchiseMembersrt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001612630us-gaap:FranchiseMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2023-01-012023-03-310001612630us-gaap:FranchiseMember2023-01-012023-03-310001612630us-gaap:FranchisedUnitsMember2023-03-31jynt:clinic0001612630us-gaap:FranchisedUnitsMember2022-03-310001612630us-gaap:FranchisedUnitsMember2022-12-310001612630us-gaap:FranchisedUnitsMember2021-12-310001612630us-gaap:FranchisedUnitsMember2023-04-012023-06-300001612630us-gaap:FranchisedUnitsMember2022-04-012022-06-300001612630us-gaap:FranchisedUnitsMember2023-01-012023-06-300001612630us-gaap:FranchisedUnitsMember2022-01-012022-06-300001612630us-gaap:FranchisedUnitsMember2023-06-300001612630us-gaap:FranchisedUnitsMember2022-06-300001612630us-gaap:EntityOperatedUnitsMember2023-03-310001612630us-gaap:EntityOperatedUnitsMember2022-03-310001612630us-gaap:EntityOperatedUnitsMember2022-12-310001612630us-gaap:EntityOperatedUnitsMember2021-12-310001612630us-gaap:EntityOperatedUnitsMember2023-04-012023-06-300001612630us-gaap:EntityOperatedUnitsMember2022-04-012022-06-300001612630us-gaap:EntityOperatedUnitsMember2023-01-012023-06-300001612630us-gaap:EntityOperatedUnitsMember2022-01-012022-06-300001612630us-gaap:EntityOperatedUnitsMember2023-06-300001612630us-gaap:EntityOperatedUnitsMember2022-06-3000016126302023-04-01jynt:corporation0001612630stpr:NC2023-04-010001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-04-012023-06-300001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-04-012022-06-300001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-06-300001612630us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-06-300001612630srt:MinimumMember2023-06-300001612630srt:MaximumMember2023-06-30jynt:option0001612630us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-06-30xbrli:pure0001612630us-gaap:RestrictedStockMember2023-04-012023-06-300001612630us-gaap:RestrictedStockMember2022-04-012022-06-300001612630us-gaap:RestrictedStockMember2023-01-012023-06-300001612630us-gaap:RestrictedStockMember2022-01-012022-06-300001612630us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001612630us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001612630us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001612630us-gaap:EmployeeStockOptionMember2022-01-012022-06-30jynt:state0001612630us-gaap:TransferredAtPointInTimeMember2023-04-012023-06-300001612630us-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001612630us-gaap:TransferredAtPointInTimeMember2023-01-012023-06-300001612630us-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001612630us-gaap:TransferredOverTimeMember2023-04-012023-06-300001612630us-gaap:TransferredOverTimeMember2022-04-012022-06-300001612630us-gaap:TransferredOverTimeMember2023-01-012023-06-300001612630us-gaap:TransferredOverTimeMember2022-01-012022-06-3000016126302023-07-012023-06-3000016126302024-01-012023-06-3000016126302025-01-012023-06-3000016126302026-01-012023-06-3000016126302027-01-012023-06-3000016126302028-01-012023-06-300001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2023-05-222023-05-220001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberus-gaap:SubsequentEventMember2023-07-012023-09-300001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2023-05-220001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberus-gaap:FranchiseRightsMember2023-05-310001612630srt:MinimumMemberjynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberus-gaap:FranchiseRightsMember2023-05-220001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberus-gaap:FranchiseRightsMembersrt:MaximumMember2023-05-220001612630us-gaap:CustomerRelationshipsMemberjynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2022-05-190001612630us-gaap:CustomerRelationshipsMemberjynt:AssetAndFranchisePurchaseAgreementCaliforniaMembersrt:MaximumMember2023-05-220001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberjynt:AssembledWorkforceMember2023-05-310001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMemberjynt:AssembledWorkforceMembersrt:MaximumMember2023-05-220001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMember2022-05-192022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:FranchiseRightsMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMembersrt:MinimumMemberus-gaap:FranchiseRightsMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:FranchiseRightsMembersrt:MaximumMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:CustomerRelationshipsMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:CustomerRelationshipsMembersrt:MaximumMember2022-05-190001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2023-04-012023-06-300001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2022-04-012022-06-300001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2023-01-012023-06-300001612630jynt:AssetAndFranchisePurchaseAgreementCaliforniaMember2022-01-012022-06-300001612630us-gaap:OfficeEquipmentMember2023-06-300001612630us-gaap:OfficeEquipmentMember2022-12-310001612630us-gaap:LeaseholdImprovementsMember2023-06-300001612630us-gaap:LeaseholdImprovementsMember2022-12-310001612630us-gaap:SoftwareDevelopmentMember2023-06-300001612630us-gaap:SoftwareDevelopmentMember2022-12-310001612630jynt:LeasedAssetsMember2023-06-300001612630jynt:LeasedAssetsMember2022-12-310001612630jynt:PropertyPlantAndEquipmentExcludingConstructionInProgressMember2023-06-300001612630jynt:PropertyPlantAndEquipmentExcludingConstructionInProgressMember2022-12-310001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:FranchiseRightsMember2022-05-310001612630jynt:AssetAndFranchisePurchaseAgreementArizonaMemberus-gaap:CustomerRelationshipsMember2022-05-310001612630us-gaap:FranchiseRightsMember2023-06-300001612630us-gaap:CustomerRelationshipsMember2023-06-300001612630jynt:AssembledWorkforceMember2023-06-300001612630us-gaap:FranchiseRightsMember2022-12-310001612630us-gaap:CustomerRelationshipsMember2022-12-310001612630jynt:AssembledWorkforceMember2022-12-310001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2020-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-02-280001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberjynt:DevelopmentLineOfCreditMember2020-02-280001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2020-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMember2022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2022-02-280001612630jynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2022-02-280001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2022-02-280001612630jynt:A2022CreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-02-280001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-02-280001612630jynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMemberjynt:DevelopmentLineOfCreditMember2022-02-282022-02-280001612630jynt:A2022CreditFacilityMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630jynt:A2022CreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMembersrt:MaximumMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:A2022CreditFacilityMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:A2022CreditFacilityMemberjynt:FederalReserveBankOfNewYorkRateMemberus-gaap:LineOfCreditMember2022-02-282022-02-280001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2023-06-300001612630us-gaap:RevolvingCreditFacilityMemberjynt:SeniorSecuredCreditFacilitiesMemberus-gaap:LineOfCreditMember2023-01-012023-06-300001612630us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001612630us-gaap:EmployeeStockOptionMember2023-06-300001612630us-gaap:EmployeeStockOptionMember2022-12-310001612630us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001612630us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001612630us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001612630us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001612630us-gaap:RestrictedStockMember2023-06-30jynt:installment0001612630us-gaap:RestrictedStockMemberjynt:CertainHighPerformingEmployeesMember2023-05-250001612630us-gaap:RestrictedStockMemberjynt:CertainHighPerformingEmployeesMember2023-05-252023-05-250001612630us-gaap:RestrictedStockMember2022-12-310001612630us-gaap:RestrictedStockMember2023-01-012023-06-300001612630us-gaap:RestrictedStockMember2023-04-012023-06-300001612630us-gaap:RestrictedStockMember2022-04-012022-06-300001612630us-gaap:RestrictedStockMember2022-01-012022-06-30jynt:leasejynt:segment0001612630jynt:CorporateClinicsMember2023-04-012023-06-300001612630jynt:CorporateClinicsMember2022-04-012022-06-300001612630jynt:CorporateClinicsMember2023-01-012023-06-300001612630jynt:CorporateClinicsMember2022-01-012022-06-300001612630jynt:FranchiseOperationsMember2023-04-012023-06-300001612630jynt:FranchiseOperationsMember2022-04-012022-06-300001612630jynt:FranchiseOperationsMember2023-01-012023-06-300001612630jynt:FranchiseOperationsMember2022-01-012022-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2023-04-012023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2022-04-012022-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2023-01-012023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2022-01-012022-06-300001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2023-04-012023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2022-04-012022-06-300001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2023-01-012023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2022-01-012022-06-300001612630us-gaap:CorporateMember2023-04-012023-06-300001612630us-gaap:CorporateMember2022-04-012022-06-300001612630us-gaap:CorporateMember2023-01-012023-06-300001612630us-gaap:CorporateMember2022-01-012022-06-300001612630us-gaap:OperatingSegmentsMember2023-04-012023-06-300001612630us-gaap:OperatingSegmentsMember2022-04-012022-06-300001612630us-gaap:OperatingSegmentsMember2023-01-012023-06-300001612630us-gaap:OperatingSegmentsMember2022-01-012022-06-300001612630us-gaap:CorporateNonSegmentMember2023-04-012023-06-300001612630us-gaap:CorporateNonSegmentMember2022-04-012022-06-300001612630us-gaap:CorporateNonSegmentMember2023-01-012023-06-300001612630us-gaap:CorporateNonSegmentMember2022-01-012022-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:CorporateClinicsMember2022-12-310001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2023-06-300001612630us-gaap:OperatingSegmentsMemberjynt:FranchiseOperationsMember2022-12-310001612630us-gaap:OperatingSegmentsMember2023-06-300001612630us-gaap:OperatingSegmentsMember2022-12-310001612630us-gaap:MaterialReconcilingItemsMember2023-06-300001612630us-gaap:MaterialReconcilingItemsMember2022-12-3100016126302023-03-012023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023 
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from __________________ to _________________
Commission file number: 001-36724
The Joint Corp.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or
organization)
90-0544160
(IRS Employer Identification No.)
16767 N. Perimeter Drive, Suite 110, Scottsdale
Arizona
(Address of principal executive offices)
85260
(Zip Code)
(480) 245-5960
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
JYNT
The NASDAQ Capital Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☐Accelerated filer☐
Non- accelerated filer☑Smaller reporting company☑
Emerging growth company
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Act).    Yes ☐    No ☑

As of September 11, 2023, the registrant had 14,754,553 shares of Common Stock ($0.001 par value) outstanding.

THE JOINT CORP.
FORM 10-Q
TABLE OF CONTENTS
PAGE
NO.
Item 1.
1
3
4
5
7
Item 2.
35
Item 3.
47
Item 4.
47
Item 1.
47
Item 1A.
47
Item 2.
49
Item 6.
51
52
53
Part II, Items 3, 4, and 5 - Not applicable


PART I: FINANCIAL INFORMATION
ITEM 1. UNAUDITED FINANCIAL STATEMENTS
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
1
June 30,
2023		December 31,
2022
ASSETS
(unaudited)
(as restated)
Current assets:
Cash and cash equivalents
$13,602,515 $9,745,066 
Restricted cash
848,831 805,351 
Accounts receivable, net
3,534,828 3,911,272 
Deferred franchise and regional development costs, current portion1,058,704 1,054,060 
Prepaid expenses and other current assets
3,306,964 2,098,359 
Assets held for sale215,722 — 
Total current assets
22,567,564 17,614,108 
Property and equipment, net
17,627,933 17,475,152 
Operating lease right-of-use asset
22,641,632 20,587,199 
Deferred franchise and regional development costs, net of current portion5,605,760 5,707,678 
Intangible assets, net
10,050,360 10,928,295 
Goodwill
8,493,407 8,493,407 
Deferred tax assets11,450,998 11,928,152 
Deposits and other assets
768,943 756,386 
Total assets$99,206,597 $93,490,377 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$1,576,085 $2,966,589 
Accrued expenses
2,342,744 1,069,610 
Co-op funds liability
848,832 805,351 
Payroll liabilities ($0.6 million and $0.6 million attributable to VIE)
2,845,800 2,030,510 
Operating lease liability, current portion5,880,954 5,295,830 
Finance lease liability, current portion24,956 24,433 
Deferred franchise fee revenue, current portion2,503,294 2,468,601 
Deferred revenue from company clinics ($5.0 million and $4.7 million attributable to VIE)
7,689,448 7,471,549 
Upfront Regional Developer Fees, current portion406,965 487,250 
Other current liabilities
693,427 597,294 
Liabilities to be disposed of155,622 — 
Total current liabilities
24,968,127 23,217,017 
Operating lease liability, net of current portion20,029,654 18,672,719 
Finance lease liability, net of current portion50,896 63,507 
Debt under the Credit Agreement2,000,000 2,000,000 
Deferred franchise revenue, net of current portion14,210,441 14,161,134 
Upfront Regional Developer Fees, net of current portion1,183,106 1,500,278 
Other liabilities
1,287,879 1,287,879 
Total liabilities
63,730,103 60,902,534 
Commitments and contingencies
Stockholders' equity:
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of June 30, 2023 and December 31, 2022
— — 
Common stock, $0.001 par value; 20,000,000 shares authorized, 14,772,520 shares issued and 14,740,485 shares outstanding as of June 30, 2023 and 14,560,353 shares issued and 14,528,487 outstanding as of December 31, 2022
14,772 14,560 
Additional paid-in capital
46,443,706 45,558,305 
Treasury stock 32,035 shares as of June 30, 2023 and 31,866 shares as of December 31, 2022, at cost
(859,279)(856,642)
Accumulated deficit
(10,147,705)(12,153,380)
Total The Joint Corp. stockholders' equity
35,451,494 32,562,843 
Non-controlling Interest
25,000 25,000 
Total equity
35,476,494 32,587,843 
Total liabilities and stockholders' equity
$99,206,597 $93,490,377 

The accompanying notes are an integral part of these condensed consolidated financial statements.
2
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)

Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
(as restated)(as restated)
Revenues:
Revenues from company-owned or managed clinics
$17,802,838 $14,492,972 $34,930,795 $27,099,971 
Royalty fees7,172,159 6,411,214 14,038,182 12,420,146 
Franchise fees671,368 686,886 1,425,794 1,327,851 
Advertising fund revenue2,041,050 1,825,757 3,993,455 3,536,474 
Software fees1,234,812 1,099,981 2,444,817 2,056,979 
Regional developer fees— — — — 
Other revenues384,957 370,555 774,962 682,695 
Total revenues29,307,184 24,887,365 57,608,005 47,124,116 
Cost of revenues:
Franchise and regional development cost of revenues2,236,442 1,904,936 4,377,277 3,705,961 
IT cost of revenues359,070 352,156 692,920 662,115 
Total cost of revenues2,595,512 2,257,092 5,070,197 4,368,076 
Selling and marketing expenses4,707,818 3,839,724 8,868,062 7,127,212 
Depreciation and amortization2,329,267 1,461,870 4,544,322 2,798,527 
General and administrative expenses19,904,796 18,570,301 39,943,272 34,103,726 
Total selling, general and administrative expenses
26,941,881 23,871,895 53,355,656 44,029,465 
Net loss on disposition or impairment144,345 88,844 209,815 95,749 
Loss from operations(374,554)(1,330,466)(1,027,663)(1,369,174)
Other income (expense), net(106,520)(19,286)3,714,642 (35,434)
(Loss) income before income tax expense(481,074)(1,349,752)2,686,979 (1,404,608)
Income tax (benefit) expense(160,585)(477,884)681,304 (536,960)
Net (loss) income $(320,489)$(871,868)$2,005,675 $(867,648)
Earnings per share:
Basic earnings per share$(0.02)$(0.06)$0.14 $(0.06)
Diluted earnings per share$(0.02)$(0.06)$0.13 $(0.06)
Basic weighted average shares14,684,035 14,475,825 14,625,435 14,454,738 
Diluted weighted average shares14,952,363 14,842,816 14,907,593 14,887,238 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(unaudited)
Common StockAdditional
Paid In
Capital		Treasury StockAccumulated
Deficit		Total The Joint Corp.
stockholders'
equity		Non-controlling
interest		Total
SharesAmountSharesAmount
Balances, December 31, 2022, as restated14,560,353 $14,560 $45,558,305 31,866 $(856,642)$(12,153,380)$32,562,843 $25,000 $32,587,843 
Stock-based compensation expense— — 266,210 — — — 266,210 — 266,210 
Issuance of restricted stock95,386 95 (95)— — — — — — 
Exercise of stock options15,621 16 138,441 — — — 138,457 — 138,457 
Purchases of treasury stock under employee stock plans— — — 169 (2,637)— (2,637)— (2,637)
Net income— — — — — 2,326,164 2,326,164 — 2,326,164 
Balances, March 31, 2023 as revised (unaudited)14,671,360 $14,671 $45,962,861 32,035 $(859,279)$(9,827,216)$35,291,037 $25,000 $35,316,037 
Stock-based compensation expense— — 417,017 — — — 417,017 — 417,017 
Issuance of restricted stock91,158 91 (91)— — — — — — 
Exercise of stock options10,002 10 63,919 — — — 63,929 — 63,929 
Net loss— — — — — (320,489)(320,489)— (320,489)
Balances, June 30, 2023 (unaudited)14,772,520 $14,772 $46,443,706 32,035 $(859,279)$(10,147,705)$35,451,494 $25,000 $35,476,494 

Common StockAdditional
Paid In
Capital		Treasury StockAccumulated
Deficit		Total The Joint Corp.
stockholders'
equity		Non-controlling
interest
SharesAmountSharesAmountTotal
(as restated)(as restated)(as restated)
Balances, December 31, 2021, as restated14,451,355 $14,450 $43,900,157 31,643 $(850,838)$(12,780,085)$30,283,684 $25,000 $30,308,684 
Stock-based compensation expense— — 323,556 — — — 323,556 — 323,556 
Issuance of restricted stock36,722 37 (37)— — — — — — 
Exercise of stock options4,972 5 49,618 — — — 49,623 — 49,623 
Purchases of treasury stock under employee stock plans— — — 74 (2,598)— (2,598)— (2,598)
Net loss— — — — — 4,220 4,220 — 4,220 
Balances, March 31, 2022, (unaudited)14,493,049 $14,492 $44,273,294 31,717 $(853,436)$(12,775,865)$30,658,485 $25,000 $30,683,485 
Stock-based compensation expense— — 340,191 — — — 340,191 — 340,191 
Issuance of restricted stock28,758 29 (29)— — — — — — 
Exercise of stock options4,610 5 64,045 — — — 64,050 — 64,050 
Net loss— — — — — (871,868)(871,868)— (871,868)
Balances, June 30, 2022, as restated(unaudited)14,526,417 $14,526 $44,677,501 31,717 $(853,436)$(13,647,733)$30,190,858 $25,000 $30,215,858 



The accompanying notes are an integral part of these condensed consolidated financial statements.
4
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
Six Months Ended
June 30,
20232022
(as restated)
Cash flows from operating activities:
Net income (loss)$2,005,675 $(867,648)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization4,544,322 2,798,527 
Net loss on disposition or impairment 209,815 95,749 
Net franchise fees recognized upon termination of franchise agreements(20,050)(15,218)
Deferred income taxes477,154 (832,083)
Stock based compensation expense683,227 663,747 
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable376,444 140,324 
Prepaid expenses and other current assets(1,208,605)(267,159)
Deferred franchise costs51,268 (193,784)
Deposits and other assets(12,557)(132,379)
Accounts payable(1,440,375)(397,040)
Accrued expenses1,104,369 (823,079)
Payroll liabilities815,290 (2,043,788)
Deferred revenue245,363 864,213 
Upfront regional developer fees(397,457)(824,658)
Other liabilities59,259 649,436 
Net cash provided by operating activities7,493,142 (1,184,840)
Cash flows from investing activities:
Acquisition of AZ clinics— (5,600,000)
Acquisition of CA clinics(1,050,000)— 
Purchase of property and equipment(2,729,875)(3,164,961)
Net cash used in investing activities(3,779,875)(8,764,961)
Cash flows from financing activities:
Payments of finance lease obligation(12,087)(38,022)
Purchases of treasury stock under employee stock plans(2,637)(2,598)
Proceeds from exercise of stock options202,386 113,673 
Net cash provided by financing activities187,662 73,053 
Increase (decrease) in cash, cash equivalents and restricted cash3,900,929 (9,876,748)
Cash, cash equivalents and restricted cash, beginning of period10,550,417 19,912,338 
Cash, cash equivalents and restricted cash, end of period$14,451,346 $10,035,590 
Reconciliation of cash, cash equivalents and restricted cash:June 30,
2023		June 30,
2022
Cash and cash equivalents$13,602,515 $9,370,611 
Restricted cash848,831 664,979 
$14,451,346 $10,035,590 

5
Supplemental cash flow disclosures:
The following table represents supplemental cash flow disclosures and non-cash investing and financing activities:
Six Months Ended
June 30,
20232022
Net cash paid for:
Interest$127,481 $23,982 
Income taxes$59,989 $59,271 
Non-cash investing and financing activity:
Unpaid purchases of property and equipment$79,871 $450,072 
Non-cash investment in acquisition of franchised clinics$28,997 $70,484 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
7
Note 1: Nature of Operations and Summary of Significant Accounting Policies
Basis of Presentation
These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”), which includes its variable interest entities (“VIEs”), and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the “Company”). The accompanying unaudited condensed consolidated interim financial statements reflect all adjustments which are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Such unaudited condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated interim financial statements should be read in conjunction with The Joint Corp. and Subsidiary and Affiliates consolidated financial statements and the notes thereto as set forth in The Joint’s Amended and Restated Form 10-K as of and for the year ended December 31, 2022, filed with the SEC on [September 13, 2023] (“Form 10-K/A”), which included all disclosures required by GAAP. The results of operations for the periods ended June 30, 2023 and 2022 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the three and six-month periods ended June 30, 2023 and 2022 is unaudited.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management’s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates. For a discussion of significant estimates and judgments made in recognizing revenue, accounting for leases, and accounting for income taxes, see Note 1, “Nature of Operations and Summary of Significant Accounting Policies.”
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of The Joint and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC, which was dormant for all periods presented. The Company consolidates VIEs in which the Company is the primary beneficiary in accordance with Accounting Standards Codification 810, Consolidations (“ASC 810”). Non-controlling interests represent third-party equity ownership interests in VIEs. All significant inter-affiliate accounts and transactions between The Joint and its VIEs have been eliminated in consolidation.
Comprehensive Income
Net income was the same as comprehensive income for the three and six months ended June 30, 2023 and 2022.
Restatement of Previously Issued Interim Consolidated Financial Statements (Unaudited and Restated)
Subsequent to the issuance of the Company's consolidated financial statements as of and for the year ended December 31, 2022, included in the Form 10-K filed with the SEC on March 10, 2023, the following errors were identified:
–The Company has historically recorded the re-acquired Regional Developer Rights as an intangible asset and amortized the re-acquired Regional Developer Rights over the contractual terms under the RD Agreement remaining at the time of the re-acquisition. The Company has concluded that this treatment was incorrect in accordance with U.S. GAAP. The Company should not have capitalized the re-acquired Regional Developer Rights but instead should have recognized the full cost of the re-acquisition as an expense in the respective period.
–The Company has historically recorded the upfront fee paid by the regional developer as a deferred liability, which was then recognized ratably to revenue as the regional developer performed various service obligations. However, the Company concluded that the deferred liability should be ratably recognized against cost of revenue as an offset against future commissions instead of revenue.
8
–The Company has historically charged the VIEs a management fee for the benefit of the Company providing non-clinical administrative services needed by the professional corporation chiropractic practice. The economic compensation or profitability resulting from an intercompany transaction between two or more parties is based on each party’s relative contribution to the economic activity under analysis. The standalone professional corporations have not historically been profitable from an income tax perspective and are fully valuing their deferred tax assets and related attributes for ASC 740 purposes. The professional corporations' earned annual losses were not consistent with their function, risk, and asset profile for transfer pricing. As such, the Company has estimated transfer pricing adjustments which were computed based on assumed targets of profitability. The resulting operating profit, after incorporating estimated transfer pricing adjustments, were further used as a means for computing overall potential tax exposure and correlative benefit.
The Company assessed the impact of these errors on its previously issued interim financial statements and determined them to be quantitatively and qualitatively material to the period ending June 30, 2022 based on its analysis of Staff Accounting Bulletin (“SAB”) No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements”. These errors have been corrected in the consolidated balance sheets as of December 31, 2022 and 2021 and the consolidated income statements, statements of changes in stockholders’ equity, and statements of cash flows for the years then ended.
The following table summarizes the effect of the errors on the Company’s consolidated balance sheet as of June 30, 2022:
June 30,
2022		June 30,
2022
As Previously Reported
Adjustments
As Restated
Intangible assets, net$9,114,701 $(2,356,584)$6,758,117 
Deferred tax assets9,116,248 3,202,634 12,318,882 
Total assets86,235,794 846,050 87,081,844 
Current liabilities:
Deferred franchise and regional development fee revenue, current portion2,981,534 (2,981,534)— 
Deferred franchise fee revenue, current portion— 2,393,993 2,393,993 
Upfront regional developer fees, current portion— 587,541 587,541 
Other current liabilities558,250 49,022 607,272 
Total current liabilities20,238,810 49,022 20,287,832 
Deferred franchise and regional development fee revenue, net of current portion15,447,554 (15,447,554)— 
Deferred franchise fee revenue, net of current portion— 13,584,091 13,584,091 
Upfront regional developer fees, net of current portion— 1,863,463 1,863,463 
Other liabilities27,230 1,064,565 1,091,795 
Total liabilities55,752,399 1,113,587 56,865,986 
Accumulated deficit(13,380,196)(267,537)(13,647,733)
Total The Joint Corp. stockholders' equity30,458,395 (267,537)30,190,858 
Total equity30,483,395 (267,537)30,215,858 
Total liabilities and stockholders' equity86,235,794 846,050 87,081,844 
9
The following table summarizes the effect of the errors on the Company’s consolidated income statement for the three and six months ended June 30, 2022:
As Previously ReportedAdjustmentsAs Restated
Three Months Ended June 30, 2022Six Months Ended June 30, 2022Three Months Ended June 30, 2022Six Months Ended June 30, 2022Three Months Ended June 30, 2022Six Months Ended June 30, 2022
Revenues:
Regional developer fees$169,953 $371,740 $(169,953)$(371,740)$— $— 
Total revenues25,057,318 47,495,856 (169,953)(371,740)24,887,365 47,124,116 
Cost of revenues:
Franchise and regional developer cost of revenues2,074,889 4,077,701 (169,953)(371,740)1,904,936 3,705,961 
Total cost of revenues2,427,045 4,739,816 (169,953)(371,740)2,257,092 4,368,076 
Depreciation and amortization1,700,476 3,329,653 (238,606)(531,126)1,461,870 2,798,527 
General and administrative expenses16,528,022 31,906,644 2,042,279 2,197,082 18,570,301 34,103,726 
Total selling, general and administrative expenses22,068,222 42,363,509 1,803,673 1,665,956 23,871,895 44,029,465 
Income from operations473,207 296,782 (1,803,673)(1,665,956)(1,330,466)(1,369,174)
Income before income tax expense (benefit)453,921 261,348 (1,803,673)(1,665,956)(1,349,752)(1,404,608)
Income tax expense (benefit)109,179 122,403 (587,063)(659,363)(477,884)(536,960)
Net income (loss)344,742 138,945 (1,216,610)(1,006,593)(871,868)(867,648)
Earnings per share:
Basic earnings (loss) per share$0.02 $0.01 $(0.08)$(0.07)$(0.06)$(0.06)
Diluted earnings (loss) per share$0.02 $0.01 $(0.08)$(0.07)$(0.06)$(0.06)
The following table summarizes the effect of the errors on the Company’s consolidated statements of stockholders' equity as of June 30, 2022, March 31, 2022 and December 31, 2021:
10
Accumulated
Deficit		Total The Joint Corp. stockholder's equity
Total Equity
Balances, December 31, 2021 (as previously reported)
$(13,519,142)$29,544,627 $29,569,627 
Adjustment due to cumulative error correction
739,057 739,057 739,057 
Balances, December 31, 2021 (as restated)$(12,780,085)$30,283,684 $30,308,684 
Balances, March 31, 2022 (as previously reported)
$(13,724,938)$29,709,412 $29,734,412 
Adjustment due to cumulative error correction
949,073 949,073 949,073 
Balances, March 31, 2022$(12,775,865)$30,658,485 $30,683,485 
Balances, June 30, 2022 (as previously reported)
$(13,380,196)$30,458,395 $30,483,395 
Adjustment due to cumulative error correction
(267,537)(267,537)(267,537)
Balances, June 30, 2022 (as restated)
$(13,647,733)$30,190,858 $30,215,858 

The following table summarizes the effect of the errors on the Company’s consolidated statement of cash flows for the six-month period ended June 30, 2022:
11
Six Months Ended June 30,
2022		Six Months Ended June 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cash flows from operating activities:
Net income (loss)$138,945 (1,006,593)$(867,648)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization3,329,653 (531,126)2,798,527 
Deferred income taxes72,386 (904,469)(832,083)
Changes in operating assets and liabilities:
Upfront regional developer fees— (824,658)(824,658)
Deferred revenue492,473 371,740 864,213 
Other liabilities404,329 245,106 649,435 
Net cash provided by (used in) operating activities1,465,160 (2,650,000)(1,184,840)
Cash flows from investing activities:
Reacquisition and termination of regional developer rights(2,650,000)2,650,000 — 
Net cash used in investing activities(11,414,961)2,650,000 (8,764,961)
Decrease in cash(9,876,748)— (9,876,748)
Correction of Immaterial Error
During the second quarter of 2023, the Company identified immaterial errors related to the first quarter of 2023 in the following: (i) the accounting for upfront regional developer fees as revenue as opposed to a reduction of cost of revenue, and (ii) the accounting for uncertain tax positions related to the Joint and VIEs transfer pricing calculation for income tax purposes.

The table below sets forth the impact of the revision on the previously issued consolidated balance sheet for the interim period ended March 31, 2023.
12
March 31, 2023
As Previously(i)
ReportedAdjustmentsAs Adjusted
ASSETS
Intangible assets, net11,905,176 (1,914,106)9,991,070 
Deferred tax assets7,708,323 3,486,439 11,194,762 
Total assets$98,050,712 $1,572,333 $99,623,045 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Deferred franchise and regional development fee revenue, current portion2,978,937 (2,978,937)— 
Deferred franchise fee revenue, current portion
— 2,487,795 2,487,795 
Upfront regional developer fees, current portion— 491,142 491,142 
Other current liabilities494,250 98,043 592,293 
Total current liabilities24,969,858 98,043 25,067,901 
Deferred franchise and regional development fee revenue, net of current portion15,682,833 (15,682,833)— 
Deferred franchise fee revenue, net of current portion— 14,233,564 14,233,564 
Upfront regional developer fees, net of current portion
— 1,449,270 1,449,270 
Other liabilities27,230 1,260,649 1,287,879 
Total liabilities62,948,315 1,358,693 64,307,008 
Stockholders' equity:
Accumulated deficit(10,040,856)213,640 (9,827,216)
Total The Joint Corp. stockholders' equity35,077,397 213,640 35,291,037 
Total equity35,102,397 213,640 35,316,037 
Total liabilities and stockholders' equity$98,050,712 $1,572,333 $99,623,045 


The table below sets forth the impact of the revision on the previously issued consolidated income statement for the interim period ended March 31, 2023.

13
Three Months Ended March, 31 2023Three Months Ended March, 31 2023
As Previously Reported
Adjustments
As Adjusted
Revenues:
Regional developer fees$149,478 $(149,478)$— 
Total revenues28,450,298 (149,478)28,300,820 
Cost of revenues:
Franchise and regional developer cost of revenues2,290,313 (149,478)2,140,835 
Total cost of revenues2,624,163 (149,478)2,474,685 
Depreciation and amortization2,342,544 (127,489)2,215,055 
General and administrative expenses19,936,115 102,361 20,038,476 
Total selling, general and administrative expenses26,438,903 (25,128)26,413,775 
Loss from operations(678,237)25,128 (653,109)
Income before income tax expense (benefit)3,142,925 25,128 3,168,053 
Income tax expense841,889 — 841,889 
Net income$2,301,036 $25,128 $2,326,164 
Earnings per share:
Basic earnings per share$0.16 $— $0.16 
Diluted earnings per share$0.15 $0.01 $0.16 
Nature of Operations
The Joint Corp., a Delaware corporation, was formed on March 10, 2010 for the principal purpose of franchising and developing chiropractic clinics, selling regional developer rights, supporting the operations of franchised chiropractic clinics, and operating and managing corporate chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.
14
The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed clinics for the three and six months ended June 30, 2023 and 2022:
Three Months Ended
June 30,		Six Months Ended
June 30,
Franchised clinics:2023202220232022
Clinics open at beginning of period740 636 712 610 
Opened during the period23 31 52 58 
Sold during the period(3)(4)(3)(4)
Closed during the period(4)(1)(5)(2)
Clinics in operation at the end of the period756 662 756 662 
Three Months Ended
June 30,		Six Months Ended
June 30,
Company-owned or managed clinics:2023202220232022
Clinics open at beginning of period130 100 126 96 
Opened during the period3 3 7 7 
Acquired during the period3 4 3 4 
Closed during the period(2)— (2)— 
Clinics in operation at the end of the period134 107 134 107 
Total clinics in operation at the end of the period890 769 890 769 
Clinic licenses sold but not yet developed171 229 171 229 
Licenses for future clinics subject to executed letters of intent43 41 43 41 
Variable Interest Entities
Certain states prohibit the “corporate practice of chiropractic,” which restricts business corporations from practicing chiropractic care by exercising control over clinical decisions by chiropractic doctors. In states which prohibit the corporate practice of chiropractic, the Company typically enters into long-term management agreements with professional corporations (“PCs”) that are owned by licensed chiropractic doctors, which, in turn, employ or contract with doctors who provide professional chiropractic care in its clinics. Under these management agreements with PCs, the Company provides, on an exclusive basis, all non-clinical services of the chiropractic practice. The Company has entered into such management agreements with four PCs, including one in New Jersey, in connection with the opening of company-managed clinics in April 2023. If an entity is deemed to be the primary beneficiary of a VIE, the entity is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. In accordance with relevant accounting guidance, these PCs were determined to be VIEs as fees paid by the PCs to the Company as its management service provider are considered variable interests because the fees do not meet all the following criteria: 1) The fees are compensation for services provided and are commensurate with the level of effort required to provide those services; 2) The decision maker or service provider does not hold other interests in the VIE that individually, or in the aggregate, would absorb more than an insignificant amount of the VIE’s
15
expected losses or receive more than an insignificant amount of the VIE’s expected residual returns; and 3) The service arrangement includes only terms, conditions, or amounts that are customarily present in arrangements for similar services negotiated at arm’s length. Additionally, the Company has determined that it has the ability to direct the activities that most significantly impact the performance of these PCs and has an obligation to absorb losses or receive benefits which could potentially be significant to the PCs. Accordingly, the PCs are VIEs for which the Company is the primary beneficiary and are consolidated by the Company.
VIE total revenue and general and administrative expenses for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
(as restated)(as restated)
Revenues$10,426,826 $8,480,265 $20,309,117 $16,283,304 
General and administrative expenses4,491,638 3,720,307 9,088,906 7,133,208 
The carrying amount of the VIEs’ assets and liabilities was immaterial as of June 30, 2023 and December 31, 2022, except for their payroll liability balances and amounts collected in advance for membership and wellness packages, which are recorded as deferred revenue. The VIEs’ payroll liability and deferred revenue from company managed clinics balances as of June 30, 2023 and December 31, 2022 were as follows:
June 30,
2023		December 31,
2022
Payroll liabilities$621,735 $586,960 
Deferred revenue from company managed clinics$4,985,654 $4,702,044 
Cash and Cash Equivalents
The Company considers all highly liquid instruments purchased with a maturity of three months or less at date of purchase to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all its cash in short-term bank deposits. The Company had no cash equivalents as of June 30, 2023 and December 31, 2022.
Restricted Cash
Restricted cash relates to cash that franchisees and company-owned or managed clinics contribute to the Company’s National Marketing Fund and cash that franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Company’s Franchise Disclosure Document with a focus on regional and national marketing and advertising. While such cash balance is not legally segregated and restricted as to withdrawal or usage, the Company's accounting policy is to classify these funds as restricted cash.
Accounts Receivable
Accounts receivable primarily represents amounts due from franchisees for royalty fees. The Company records an allowance for credit losses as a reduction to its accounts receivables for amounts that the Company does not expect to recover. An allowance for credit losses is determined through assessments of collectability based on historical trends, the financial condition of the Company’s franchisees, including any known or anticipated bankruptcies, and an evaluation of current economic conditions, as well as the
16
Company’s expectations of conditions in the future. Actual losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of June 30, 2023 and December 31, 2022, the Company had an allowance for doubtful accounts of $0.
Property and Equipment
Property and equipment are stated at cost or for property acquired as part of franchise acquisitions at fair value at the date of closing. Depreciation is computed using the straight-line method over estimated useful lives, which is generally three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income. The losses on disposed of or retired property or equipment were recorded in net loss on disposition or impairment of $144,345 and $209,815 for the three and six months ended June 30, 2023, respectively. The losses on disposed of or retired property or equipment were recorded in net loss on disposition or impairment of $88,844 and $95,749 for the three and six months ended June 30, 2022, respectively.
Leases
The Company leases property and equipment under operating and finance leases. The Company leases its corporate office space and the space for each of the company-owned or managed clinics in the portfolio. The Company recognizes a right-of-use ("ROU") asset and lease liability for all leases. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company’s sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the right-of-use asset and lease liability. When available, the Company uses the rate implicit in the lease to discount lease payments; however, the rate implicit in the lease is not readily determinable for substantially all of its leases. In such cases, the Company estimates its incremental borrowing rate as the interest rate it would pay to borrow an amount equal to the lease payments over a similar term, with similar collateral as in the lease, and in a similar economic environment. The Company estimates these rates using available evidence such as rates imposed by third-party lenders to the Company in recent financings or observable risk-free interest rate and credit spreads for commercial debt of a similar duration, with credit spreads correlating to the Company’s estimated creditworthiness.

For operating leases that include rent holidays and rent escalation clauses, the Company recognizes lease expense on a straight-line basis over the lease term from the date it takes possession of the leased property. Pre-opening costs are recorded as incurred in general and administrative expenses. Variable lease payments, such as percentage rentals based on location sales, periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred and are also included in general and administrative expenses on the accompanying consolidated income statements.
Long-Lived Assets
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets are recoverable. The Company records an impairment loss when the carrying amount of the asset is not recoverable and exceeds its fair value. During the three and six months ended June 30, 2022, the Company recorded a noncash impairment loss of $60,580 in connection with reporting the long-lived assets held for sale at two company-managed clinics at the lower of their carrying value or fair value as of June 30, 2022.
In connection with the planned sale of a company-managed clinic, the Company reclassified $159,472 of property and equipment and $116,451 of ROU assets to Assets held for sale, and reclassified $148,846 of ROU liability and $6,776 of deferred revenue from company clinics to Liabilities to be disposed of, in the consolidated balance sheet as of June 30, 2023. Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. As a result, the
17
Company recorded a valuation allowance of $60,201 to adjust the carrying value of the disposal group to fair value less cost to sell during the three and six months ended June 30, 2023.
Revenue Recognition
The Company generates revenue primarily through its company-owned and managed clinics and through royalties, franchise fees, advertising fund contributions, IT related income and computer software fees from its franchisees.
Revenues from Company-Owned or Managed Clinics. The Company earns revenues from clinics that it owns and operates or manages throughout the United States. Revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed. Any unused visits associated with monthly memberships are recognized on a month-to-month basis. The Company recognizes a contract liability (or a deferred revenue liability) related to the prepaid treatment plans for which the Company has an ongoing performance obligation. The Company derecognizes this contract liability, and recognizes revenue, as the patient consumes his or her visits related to the package and the Company transfers its services. If the Company determines that it is not subject to unclaimed property laws for the portion of wellness package that it does not expect to be redeemed (referred to as “breakage”) then it recognizes breakage revenue in proportion to the pattern of exercised rights by the patient.
Royalties and Advertising Fund Revenue. The Company collects royalties from its franchisees, as stipulated in the franchise agreement, equal to 7% of gross sales and a marketing and advertising fee currently equal to 2% of gross sales. Royalties, including franchisee contributions to advertising funds, are calculated as a percentage of clinic sales over the term of the franchise agreement. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which generally requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price). Franchise agreement royalties, inclusive of advertising fund contributions, represent sales-based royalties that are related entirely to the Company’s performance obligation under the franchise agreement, and therefore, such royalties are recognized as franchisee clinic level sales occur. Royalties are collected semi-monthly, two working days after each sales period has ended.
Franchise Fees. The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of ten years. Initial franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement. The Company’s services under the franchise agreement include training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation. Renewal franchise fees, as well as transfer fees, are also recognized as revenue on a straight-line basis over the term of the respective franchise agreement.
Software Fees. The Company collects a monthly fee from its franchisees for use of its proprietary chiropractic software, computer support, and internet services support. These fees are recognized ratably on a straight-line basis over the term of the respective franchise agreement.
Capitalized Sales Commissions. Sales commissions earned by the regional developers and the Company’s sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.
Regional Developer Fees
18
The Company has a regional developer program where regional developers are granted an exclusive geographical territory and commit to a minimum development obligation within that defined territory. Regional developer fees paid to the Company are non-refundable and are amortized on a straight-line basis over the term of the regional developer agreement and recognized as a decrease to franchise cost of revenues.
In addition, regional developers receive fees which are funded by the initial franchise fees collected from franchisees upon the sale of franchises within their exclusive geographical territory and a royalty of 3% of sales generated by franchised clinics in their exclusive geographical territory. Initial fees related to the sale of franchises within their exclusive geographical territory are initially deferred as deferred franchise costs and are recognized as an expense in franchise cost of revenues when the respective revenue is recognized, which is generally over the term of the related franchise agreement. Royalties of 3% of sales generated by franchised clinics in their regions are also recognized as franchise cost of revenues as franchisee clinic level sales occur. This 3% fee is funded by the 7% royalties collected from the franchisees in their regions. Certain regional developer agreements result in the regional developer acquiring the rights to existing royalty streams from clinics already open in the respective territory. In those instances, the revenue associated from the sale of the royalty stream is recognized over the remaining life of the respective franchise agreements. The Company did not enter into any new regional developer agreements during the six months ended June 30, 2023 and 2022.
Advertising Costs
Advertising costs are advertising and marketing expenses incurred by the Company, primarily through advertising funds. The Company expenses production costs of commercial advertising upon first airing and expenses the costs of communicating the advertising in the period in which the advertising occurs. Advertising expenses were $1,977,678 and $3,578,291 for the three and six months ended June 30, 2023, respectively. Advertising expenses were $1,104,156 and $2,318,568 for the three and six months ended June 30, 2022, respectively.
Income Taxes
Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date pre-tax income, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected pre-tax income for the year and permanent differences. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.
Earnings per Common Share
Basic earnings per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is computed by giving effect to all potentially dilutive common shares including restricted stock and stock options.
19
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
(as restated)(as restated)
Net (loss) income$(320,489)$(871,868)$2,005,675 $(867,648)
Weighted average common shares outstanding - basic14,684,035 14,475,825 14,625,435 14,454,738 
Effect of dilutive securities:
Unvested restricted stock and stock options268,328 366,991 282,158 432,500 
Weighted average common shares outstanding - diluted14,952,363 14,842,816 14,907,593 14,887,238 
Basic (loss) earnings per share$(0.02)$(0.06)$0.14 $(0.06)
Diluted (loss) earnings per share$(0.02)$(0.06)$0.13 $(0.06)
The following common stock equivalents were excluded from the computation of diluted earnings (loss) per share for the periods presented because including them would have been antidilutive:
Three Months Ended
June 30,		Six Months Ended
June 30,
Weighted average dilutive securities:2023202220232022
Restricted stocks— — — — 
Stock options87,983 43,120 90,953 42,064 
Stock-Based Compensation
The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using the closing price on the date of the grant and the grant-date fair value of stock options using the Black-Scholes-Merton model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.
Loss Contingencies
ASC Topic 450 governs the disclosure of loss contingencies and accrual of loss contingencies in respect of litigation and other claims. The Company records an accrual for a potential loss when it is probable that a loss will occur and the amount of the loss can be reasonably estimated. When the reasonable estimate of the potential loss is within a range of amounts, the minimum of the range of potential loss is accrued, unless a higher amount within the range is a better estimate than any other amount within the range. Moreover, even if an accrual is not required, the Company provides additional disclosure related to litigation and other claims when it is reasonably possible (i.e., more than
20
remote) that the outcomes of such litigation and other claims include potential material adverse impacts on the Company. Legal costs to be incurred in connection with a loss contingency are expensed as such costs are incurred.
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for credit losses, loss contingencies, share-based compensations, useful lives and realizability of long-lived assets, deferred revenue and revenue recognition related to breakage, deferred franchise costs, calculation of ROU assets and liabilities related to leases, realizability of deferred tax assets, impairment of goodwill, intangible assets, other long-lived assets, and purchase price allocations and related valuations.
Recent Accounting Pronouncements Adopted and Not Yet Adopted

The Company reviewed newly issued accounting pronouncements and concluded that they either are not applicable to the Company's operations or that no material effect is expected on the Company's financial statements upon future adoption.
21
Note 2: Revenue Disclosures
Company-owned or Managed Clinics
The Company earns revenues from clinics that it owns and operates or manages throughout the United States. Revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages which feature discounted pricing as compared with its single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed or in accordance with the Company’s breakage policy as discussed in Note 1, Revenue Recognition.
Franchising Fees, Royalty Fees, Advertising Fund Revenue, and Software Fees
The Company currently franchises its concept across 41 states, the District of Columbia and Puerto Rico. The franchise arrangement is documented in the form of a franchise agreement. The franchise arrangement requires the Company to perform various activities to support the brand that do not directly transfer goods and services to the franchisee, but instead represent a single performance obligation, which is the transfer of the franchise license. The intellectual property subject to the franchise license is symbolic intellectual property as it does not have significant standalone functionality, and substantially all of the utility is derived from its association with the Company’s past or ongoing activities. The nature of the Company’s promise in granting the franchise license is to provide the franchisee with access to the brand’s symbolic intellectual property over the term of the license. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation.
The transaction price in a standard franchise arrangement primarily consists of (a) initial franchise fees; (b) continuing franchise fees (royalties); (c) advertising fees; and (d) software fees. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which otherwise requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price).
The Company recognizes the primary components of the transaction price as follows:
•Initial and renewal franchise fees, as well as transfer fees, are recognized as revenue ratably on a straight-line basis over the term of the respective franchise agreement, commencing with the execution of the franchise, renewal, or transfer agreement. As these fees are typically received in cash at or near the beginning of the contract term, the cash received is initially recorded as a contract liability until recognized as revenue over time.
•The Company is entitled to royalties and advertising fees based on a percentage of the franchisee's gross sales as defined in the franchise agreement. Royalty and advertising revenue are recognized when the franchisee's sales occur. Depending on timing within a fiscal period, the recognition of revenue results in either what is considered a contract asset (unbilled receivable) or, once billed, accounts receivable, on the balance sheet.
•The Company is entitled to a software fee, which is charged monthly. The Company recognizes revenue related to software fees ratably on a straight-line basis over the term of the franchise agreement.
In determining the amount and timing of revenue from contracts with customers, the Company exercises significant judgment with respect to collectability of the amount; however, the timing of recognition does not require significant judgment as it is based on either the franchise term or the reported sales of the franchisee, none of which require estimation. The Company believes its franchising arrangements do not contain a significant financing component.
The Company recognizes advertising fees received under franchise agreements as advertising fund revenue.
Capitalized Sales Commissions
Sales commissions earned by the regional developers and the Company’s sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.
Disaggregation of Revenue
22
The Company believes that the captions contained on the condensed consolidated income statements appropriately reflect the disaggregation of its revenue by major type for the three and six months ended June 30, 2023 and 2022. Other revenues primarily consist of preferred vendor royalties associated with franchisees' credit card transactions.
The following table shows the Company's revenues disaggregated according to the timing of transfer of services:
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
(as restated)(as restated)
Revenue recognized at a point in time$27,401,004 $23,100,498 $53,737,394 $43,739,286 
Revenue recognized over time1,906,180 1,786,867 3,870,611 3,384,830 
Total Revenues$29,307,184 $24,887,365 $57,608,005 $47,124,116 
Rollforward of Contract Liabilities and Contract Assets
Changes in the Company's contract liability for deferred revenue from company clinics during the six months ended June 30, 2023 were as follows:
Deferred Revenue from company clinics
Balance at December 31, 2022$7,471,549 
Revenue recognized that was included in the contract liability at the beginning of the year(5,202,787)
Net increase during the six months ended June 30, 20235,420,686 
Balance at June 30, 2023$7,689,448 
Changes in the Company's contract liability for deferred franchise fees during the six months ended June 30, 2023 were as follows:
Deferred Revenue
short and long-term
Balance at December 31, 2022, as restated$16,629,735 
Revenue recognized that was included in the contract liability at the beginning of the year(1,363,506)
Net increase during the six months ended June 30, 20231,447,506 
Balance at June 30, 2023$16,713,735 
The Company's deferred franchise and development costs represent capitalized sales commissions. Changes during the six months ended June 30, 2023 were as follows:
Deferred Franchise and Development Costs
short and long-term
Balance at December 31, 2022$6,761,738 
Recognized as cost of revenue during the six months ended June 30, 2023(490,939)
Net increase during the six months ended June 30, 2022393,665 
Balance at June 30, 2023$6,664,464 
23
The following table illustrates estimated revenues expected to be recognized in the future related to performance obligations that were unsatisfied (or partially unsatisfied) as of June 30, 2023:
Contract liabilities expected to be recognized inAmount
2023 (remainder)$1,272,496 
20242,459,511 
20252,322,249 
20262,228,012 
20272,154,886 
Thereafter6,276,581 
Total$16,713,735 

Note 3: Acquisitions and Assets Held for Sale
2023 Acquisition
On May 22, 2023, the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the sellers three operating franchised clinics in California (the “CA Clinics Purchase”). As of the acquisition date, the Company operates the franchises as company-managed clinics. The total purchase price for the transactions was $1,188,764 to the seller (of which $109,767 is to be paid in the third quarter of 2023)., less $28,997 of net deferred revenue, resulting in total purchase consideration of $1,159,767.

Based on the terms of the purchase agreement, the CA Clinics Purchase has been treated as an asset purchase under GAAP as there were no outputs or processes to generate outputs acquired as part of these transactions. Under an asset purchase, assets are recognized based on their cost to the acquiring entity. Cost is allocated to the individual assets acquired or liabilities assumed based on their relative fair values and does not give rise to goodwill.
The allocation of the total purchase price of the CA Clinics Purchase was as follows:
Property and equipment$313,995 
Operating lease right-of-use asset317,662 
Intangible assets1,004,513 
Total assets acquired1,636,170 
Deferred revenue(158,365)
Operating lease liability - current portion(118,081)
Operating lease liability - net of current portion(199,957)
Net purchase consideration$1,159,767 
Intangible assets in the table above primarily consist of reacquired franchise rights of $0.7 million amortized over their estimated useful lives of six to seven years, customer relationships of $0.1 million amortized over an estimated useful life of two years, and assembled workforce of $0.2 million amortized over an estimated useful life of two years.
2022 Acquisition
On May 19, 2022, the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller four operating franchises in Arizona (the “Acquisition”). The Company operates the franchises as company-owned clinics. The total purchase price for the transaction was $5,761,256, less $70,484 of net deferred revenue, resulting in total purchase consideration of $5,690,772. Based on the terms of the purchase agreement, the Acquisition was treated as a business combination under GAAP using the acquisition method of accounting, which requires that assets acquired and liabilities assumed
24
be recorded at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
The allocation of the purchase price was as follows:
Property and equipment$235,558 
Operating lease right-of-use asset823,869 
Intangible assets2,983,200 
Total identifiable assets acquired4,042,627 
Goodwill2,965,375 
Deferred revenue (493,060)
Operating lease liability – current portion (107,694)
Operating lease liability – net of current portion (716,476)
Net purchase consideration$5,690,772 
Intangible assets in the table above consist of re-acquired franchise rights of $2,422,500 amortized over estimated useful lives of approximately four to eight years and customer relationships of $560,700 amortized over estimated useful lives of two years. The fair value of re-acquired franchise rights are estimated using the multi-period excess earnings method. The multi-period excess earnings method model estimates revenues and cash flows derived from the primary asset and then deducts portions of the cash flow that can be attributed to supporting assets, such as assembled workforce and working capital that contributed to the generation of the cash flows. The resulting cash flow, which is attributable solely to the primary asset acquired, is then discounted at a rate of return commensurate with the risk of the asset to calculate a present value. Customer relationships are also calculated using the multi-period excess earnings method.
Goodwill represents the excess of the purchase consideration over the fair value of the underlying acquired net tangible and intangible assets. The factors that contributed to the recognition of goodwill included synergies and benefits expected to be gained from leveraging the Company’s existing operations and infrastructures, as well as the expected associated revenue and cash flow projections. Goodwill has been allocated to the Company’s Corporate Clinics segment based on such expected benefits. Goodwill related to the acquisition is expected to be deductible for income tax purposes over 15 years.
Pro Forma Results of Operations (Unaudited)

The following table summarizes selected unaudited pro forma consolidated income statements for three and six months ended June 30, 2023 and 2022 for the 2023 and 2022 acquisitions, as if the CA Clinics Purchase (which has been accounted for as an asset purchase) in 2023 and the AZ clinics acquired (which have been accounted for as a business combination) had both been completed on January 1, 2022.

Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
(as restated)(as restated)
Revenues, net$29,684,349 $25,601,056 $58,346,746 $48,910,697 
Net income (loss)(304,758)$(1,022,274)$1,983,969 $(1,196,652)
$29,379,591 $24,578,782 $60,330,715 $47,714,045 
The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the purchases had taken place on January 1, 2022 or of results that may occur in the future. For 2022 and 2023, this information includes actual data recorded in the Company’s consolidated financial statements for the period subsequent to the dates of the respective acquisitions.
The Company’s consolidated income statements for the three and six months ended June 30, 2023 include $168,719 in net revenue and $42,036 in net income, excluding corporate clinics segment overhead costs, of the acquired CA clinics. The
25
Company’s condensed consolidated income statements for the three and six months ended June 30, 2022 include net revenue and net income of $768,971 and $307,497, respectively, attributable to the AZ Acquisition.
Assets Held for Sale
In June 2023, the Company entered into negotiations to sell one of its company-managed clinics in California to a franchisee for a total of $0.1 million. The sale is expected to close during the third quarter of 2023, subject to the execution of the purchase agreement and other customary closing conditions contained in the purchase agreement. This transaction does not represent a strategic shift for the Company, and, therefore, it does not meet the criteria to be classified as a discontinued operation. As a result, the results of this clinic will continue to be reported in the Company’s operating results and in its Corporate Clinics segment until the sale is finalized. Effective with the designation as held for sale in June 2023, the Company discontinued recording depreciation on property and equipment, net and amortization of ROU assets for the clinic as required by GAAP. The Company also separately classified the related assets and liabilities of the clinics as held for sale in its June 30, 2023 condensed consolidated balance sheet.
Long-lived assets that meet the criteria for the held for sale designation are reported at the lower of their carrying value or fair value less estimated cost to sell. As a result of its evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the agreed upon sales price, the Company recorded an estimated loss on disposal of $60,201 during the three and six months ended June 30, 2023 as Net loss on disposition or impairment in its condensed consolidated income statement and a valuation allowance included in assets held for sale on its condensed consolidated balance sheet.

The principal components of the held for sale assets and liabilities as of June 30, 2023 were as follows:

June 30, 2023
Assets
Property and equipment, net
159,472 
Operating lease right-of-use asset116,451 
Valuation allowance$(60,201)
Total assets held for sale$215,722 
Liabilities
Operating lease liability, current and non-current148,846 
Deferred revenue from company clinics6,776 
Total liabilities to be disposed of$155,622 
26
Note 4: Property and Equipment
Property and equipment consist of the following, excluding amounts related to properties classified as held for sale:
June 30,
2023		December 31,
2022
Office and computer equipment$5,814,911 $5,207,833 
Leasehold improvements19,325,917 17,842,901 
Software developed6,163,961 5,843,758 
Finance lease assets151,396 151,396 
31,456,185 29,045,888 
Accumulated depreciation and amortization(14,931,581)(12,675,085)
16,524,604 16,370,803 
Construction in progress1,103,329 1,104,349 
Property and equipment, net$17,627,933 $17,475,152 
Depreciation expense was $1,376,474 and $941,121 for the three months ended June 30, 2023 and 2022, respectively. Depreciation expense was $2,646,735 and $1,820,251 for the six months ended June 30, 2023 and 2022, respectively.
Amortization expense related to finance lease assets was $7,570 and $18,636 for the three months ended June 30, 2023 and 2022, respectively. Amortization expense related to finance lease assets was $15,139 and $40,432 for the six months ended June 30, 2023 and 2022, respectively.
Construction in progress at June 30, 2023 and December 31, 2022 principally related to development and construction costs for the company-owned or managed clinics.
Note 5: Fair Value Measurements
The Company’s financial instruments include cash, restricted cash, accounts receivable, accounts payable, accrued expenses and debt under the Credit Agreement (defined in Note 7). The carrying amounts of its financial instruments, except for debt, approximate their fair value due to their short maturities. The carrying value of the Company's debt under the Credit Agreement approximates fair value due to its interest rate being calculated from observable quoted prices for similar instruments, which is considered a Level 2 fair value measurement.
Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:
Level 1:    Observable inputs such as quoted prices in active markets;
Level 2:    Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3:    Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
As of June 30, 2023 and December 31, 2022, the Company did not have any financial instruments that were measured on a recurring basis as Level 1, 2 or 3.
The Company’s non-financial assets, which primarily consist of goodwill, intangible assets, property, plant and equipment, and operating lease right-of-use assets, are not required to be measured at fair value on a recurring basis, and instead are reported at their carrying amount. However, on a periodic basis whenever events or changes in circumstances indicate that their carrying
27
amount may not be fully recoverable (and at least annually for goodwill), non-financial assets are assessed for impairment. If the fair value is determined to be lower than the carrying amount, an impairment charge is recorded to write down the asset to its fair value, which is considered Level 3 within the fair value hierarchy.
The assets and liabilities resulting from the Acquisitions (reference Note 3) were recorded at fair values on a nonrecurring basis and are considered Level 3 within the fair value hierarchy.
In connection with the planned sale of a company-managed clinic to a franchisee, the Company reclassified $159,472 of net property and equipment and $116,451 of ROU assets to Assets held for sale and reclassified $148,846 of lease liability and $6,776 of deferred revenue from Company clinics to Liabilities to be disposed of in the consolidated balance sheet as of June 30, 2023. Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. As a result, the Company recorded a valuation allowance of $60,201 to adjust the carrying value of the disposal group to fair value less cost to sell during the three and six months ended June 30, 2023. The estimated fair value of assets held for sale is based upon Level 2 inputs, which includes a potential buyer agreed upon selling price.
Note 6: Intangible Assets
In May 2022, the Company recognized $2.4 million and $0.6 million of reacquired franchise rights and customer relationships, respectively, from the Acquisition (reference Note 3).
In May 2023, the Company recognized $0.7 million, $0.1 million and $0.2 million of reacquired franchise rights, customer relationships and acquired workforce, respectively, from the Acquisition (reference Note 3).
Intangible assets consisted of the following:
As of June 30, 2023
Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Value
Intangible assets subject to amortization:
Reacquired franchise rights$13,594,191 $(5,802,132)$7,792,059 
Customer relationships4,444,849 (2,937,539)1,507,310 
Assembled workforce1,137,569 (386,578)750,991 
$19,176,609 $(9,126,249)$10,050,360 
As of December 31, 2022
As Restated
Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Value
Intangible assets subject to amortization:
Reacquired franchise rights$12,881,894 $(4,755,286)$8,126,608 
Customer relationships4,330,365 (2,352,500)1,977,865 
Assembled workforce959,837 (136,015)823,822 
$18,172,096 $(7,243,801)$10,928,295 
Amortization expense related to the Company’s intangible assets was $945,223 and $502,113 for the three months ended June 30, 2023 and 2022, respectively. Amortization expense was $1,882,448 and $937,844 for the six months ended June 30, 2023 and 2022, respectively.
28
Estimated amortization expense for 2023 and subsequent years is as follows:
Amount
2023 (remainder)$1,911,358 
20242,824,441 
20251,699,025 
20261,324,974 
2027769,942 
Thereafter$1,520,620 
Total$10,050,360 

Note 7: Debt
Credit Agreement
On February 28, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”), with JPMorgan Chase Bank, N.A., individually, and as Administrative Agent and Issuing Bank (“JPMorgan Chase” or the “Lender”). The Credit Agreement provided for senior secured credit facilities (the "Credit Facilities") in the amount of $7,500,000, including a $2,000,000 revolver (the "Revolver") and $5,500,000 development line of credit (the "Line of Credit"). The Revolver included amounts available for letters of credit of up to $1,000,000 and an uncommitted additional amount of $2,500,000. All outstanding principal and interest on the Revolver were due on February 28, 2022.
On February 28, 2022, the Company entered into an amendment to its Credit Facilities (as amended, the “2022 Credit Facility”) with the Lender. Under the 2022 Credit Facility, the Revolver increased to $20,000,000 (from $2,000,000), the portion of the Revolver available for letters of credit increased to $5,000,000 (from $1,000,000), the uncommitted additional amount increased to $30,000,000 (from $2,500,000) and the developmental line of credit of $5,500,000 was terminated. The Revolver will be used for working capital needs, general corporate purposes and for acquisitions, development and capital improvement uses. At the option of the Company, borrowings under the 2022 Credit Facility bear interest at: (i) the adjusted SOFR rate, plus 0.10%, plus 1.75%, payable on the last day of the selected interest period of one, three or six months, and on the three-month anniversary of the beginning of any six month interest period, if applicable; or (ii) an Alternative Base Rate (ABR), plus 1.00%, payable monthly. The ABR is the greatest of: (A) the prime rate (as published by the Wall Street Journal), (B) the Federal Reserve Bank of New York rate, plus 0.5%, and (C) the adjusted one-month term SOFR rate. Amounts outstanding under the Revolver on February 28, 2022 continued to bear interest at the rate selected under the Credit Facilities prior to the amendment until the last day of the interest period in effect, at which time, if not repaid, the amounts outstanding under the Revolver will bear interest at the 2022 Credit Facility rate. The 2022 Credit Facility will terminate and all principal and interest will become due and payable on the fifth anniversary of the amendment (February 28, 2027).

The Credit Facilities contain customary events of default, including but not limited to nonpayment; material inaccuracy of representations and warranties; violations of covenants; certain bankruptcies and liquidations; cross-default to material indebtedness; certain material judgments; and certain fundamental changes such as a merger or sale of substantially all assets (as further defined in the Credit Facilities). The Credit Facilities require the Company to comply with customary affirmative, negative and financial covenants, including minimum interest coverage and maximum net leverage. A breach of any of these operating or financial covenants would result in a default under the Credit Facilities. If an event of default occurs and is continuing, the lenders could elect to declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. The Credit Facilities are collateralized by substantially all of the Company’s assets, including the assets in the Company’s company-owned or managed clinics. The interest rate on funds borrowed under the Revolver as of June 30, 2023 was 7.1%. As of June 30, 2023, the Company was in compliance with all applicable financial and non-financial covenants under the Credit Agreement, and $2,000,000 remains outstanding as of June 30, 2023. Subsequent to June 30, 2023, a financial reporting covenant had not been met, which the lender waived the reporting requirement and extended the date for the report to be provided through September 30, 2023. Upon the filing of this form 10-Q, the Company is in compliance with its financial reporting covenant.
Note 8: Stock-Based Compensation 
The Company grants stock-based awards under its Amended and Restated 2014 Incentive Stock Plan (the “2014 Plan”). The shares issued as a result of stock-based compensation transactions generally have been funded with the issuance of new shares of the Company’s common stock. The Company may grant the following types of incentive awards under the 2014 Plan: (i) non-
29
qualified stock options; (ii) incentive stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) restricted stock units. Each award granted under the 2014 Plan is subject to an award agreement that incorporates, as applicable, the exercise price, the term of the award, the periods of restriction, the number of shares to which the award pertains, and such other terms and conditions as the plan committee determines. Awards granted under the 2014 Plan are classified as equity awards, which are recorded in stockholders’ equity in the Company’s consolidated balance sheets. Through June 30, 2023, the Company has granted under the 2014 Plan (i) non-qualified stock options; (ii) incentive stock options; and (iii) restricted stock. There were no stock appreciation rights and restricted stock units granted under the 2014 Plan as of June 30, 2023.
Stock Options
The Company’s closing price on the date of grant is the basis of fair value of its common stock used in determining the value of share-based awards. To the extent the value of the Company’s share-based awards involves a measure of volatility, the Company uses available historical volatility of the Company’s common stock over a period of time corresponding to the expected stock option term. The Company historically has used the simplified method to calculate the expected term of stock option grants to employees as the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. Accordingly, the expected life of the options granted is based on the average of the vesting term, which is generally four years and the contractual term, which is generally ten years. The Company will continue to evaluate the appropriateness of utilizing such method. The risk-free interest rate is based on United States Treasury yields in effect at the date of grant for periods corresponding to the expected stock option term. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.
The Company did not grant options during the three and six months ended June 30, 2023 and 2022.
The information below summarizes the stock options activity for the six months ended June 30, 2023:
Number of
Shares		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual Life
(Years)
Outstanding at December 31, 2022531,923 $9.20 4.7
Granted— — 
Exercised(25,623)7.90 
Cancelled(7,375)28.58 
Expired(2,591)36.19 
Outstanding at June 30, 2023496,334 $8.84 4.1
Exercisable at June 30, 2023462,490 $7.27 3.9
For the three months ended June 30, 2023 and 2022, stock-based compensation expense for stock options was $85,724 and $136,352, respectively. For the six months ended June 30, 2023 and 2022, stock-based compensation expense for stock options was $150,606 and $307,355, respectively.
Restricted Stock
Restricted stock granted to employees generally vests in four equal annual installments, although on May 25, 2023, the Company granted 51,401 shares of restricted stock as part of a special award to certain high performing employees that vest in one installment on the first anniversary of the grant. Restricted stock granted to non-employee directors typically vests in full one year after the date of grant.
The information below summarizes the restricted stock activity for the six months ended June 30, 2023:
30
Restricted Stock AwardsSharesWeighted Average
Grant-Date Fair
Value per Award
Non-vested at December 31, 202270,312 $29.05 
Granted189,569 14.84 
Vested(33,474)22.00 
Cancelled(5,348)37.01 
Non-vested at June 30, 2023221,059 $17.74 
For the three months ended June 30, 2023 and 2022, stock-based compensation expense for restricted stock was $331,293 and $203,839, respectively. For the six months ended June 30, 2023 and 2022, stock-based compensation expense for restricted stock was $532,621 and $356,392, respectively.
Note 9: Income Taxes
During the three months ended June 30, 2023 and 2022, the Company recorded income tax benefit of $160,585 and income tax benefit of $477,884, respectively. During the six months ended June 30, 2023 and 2022, the Company recorded income tax expense of $681,304 and income tax benefit of $536,960, respectively. The Company’s effective tax rates differ from the federal statutory tax rate due to permanent differences, discrete items and state taxes. The Company’s effective tax rate differs from the statutory rate for the six months ended June 30, 2023 primarily due to the company’s ERC refunds from the Internal Revenue Service. The tax effect of the refund amount, net of the related consulting fees, is treated as a discrete item for the six months ended June 30, 2023 (See Note 11 "Employee Retention Credit"). The effective tax rate for the three months ended June 30, 2023 and for the three and six months ended June 30, 2022 differs from the statutory rate primarily due to the pre-tax income reported by the Joint Corp., without the VIEs.
Note 10: Commitments and Contingencies
Leases
The table below summarizes the components of lease expense and income statement location for the three and six months ended June 30, 2023 and 2022:

Line Item in the
Company’s Condensed Consolidated
Income Statements		Three Months Ended
June 30, 2023		Three Months Ended
June 30, 2022		Six Months Ended
June 30, 2023		Six Months Ended
June 30, 2022
Finance lease costs:
Amortization of assetsDepreciation and amortization$7,570 $18,636 $15,139 $40,432 
Interest on lease liabilitiesOther expense, net825 1,112 1,713 2,549 
Total finance lease costs8,395 19,748 16,852 42,981 
Operating lease costsGeneral and administrative expenses1,639,749 $1,375,574 3,253,595 $2,730,884 
Total lease costs$1,648,144 $1,395,322 $3,270,447 $2,773,865 
31
Supplemental information and balance sheet location related to leases is as follows:
June 30, 2023December 31, 2022
Operating Leases:
Operating lease right-of -use asset$22,641,632$20,587,199
Operating lease liability - current portion$5,880,954$5,295,830
Operating lease liability - net of current portion20,029,65418,672,719
Total operating lease liability$25,910,608$23,968,549
Finance Leases:
Property and equipment, at cost$151,396$151,396
Less accumulated amortization(102,792)(87,652)
Property and equipment, net$48,604$63,744
Finance lease liability - current portion24,95624,433
Finance lease liability - net of current portion50,89663,507
Total finance lease liabilities$75,852$87,940
Weighted average remaining lease term (in years):
Operating leases5.25.4
Finance lease2.93.4
Weighted average discount rate:
Operating leases5.1 %4.8 %
Finance leases4.3 %4.3 %
Supplemental cash flow information related to leases is as follows:
Six Months Ended
June 30, 2023		Six Months Ended
June 30, 2022
Cash paid for amounts included in measurement of liabilities:
Operating cash flows from operating leases$3,465,890 $2,822,523 
Operating cash flows from finance leases1,713 2,549 
Financing cash flows from finance leases12,087 38,022 
Non-cash transactions: ROU assets obtained in exchange for lease liabilities
Operating lease$3,859,696 $2,071,960 
Finance lease— — 
`
32
Maturities of lease liabilities as of June 30, 2023 were as follows:
Operating LeasesFinance Lease
2023 (remainder)$3,545,028 $13,800 
20246,743,929 27,600 
20256,127,339 27,600 
20264,277,431 11,500 
20273,271,135 — 
Thereafter5,583,282 — 
Total lease payments$29,548,144 $80,500 
Less: Imputed interest(3,637,536)(4,647)
Total lease obligations25,910,608 75,852 
Less: Current obligations(5,880,954)(24,956)
Long-term lease obligation$20,029,654 $50,896 
During the second quarter of 2023, the Company entered into various operating leases that have not yet commenced for spaces to be used by the Company’s new corporate clinics. These leases are expected to result in additional ROU assets and liabilities of approximately $0.4 million. These leases are expected to commence during the third and the fourth quarters of 2023, with lease terms of five to ten years.
Guarantee in Connection with the Sale of the Divested Business
In connection with the sale of a company-managed clinic in 2022, the Company guaranteed one future operating lease commitment assumed by the buyers. The Company is obligated to perform under the guarantee if the buyers fail to perform under the lease agreement at any time during the remainder of the lease agreement, which expires on May 31, 2027. At the date of sale, the undiscounted maximum potential future payments totaled $247,296. As of June 30, 2023, the undiscounted remaining lease payments under the agreement totaled $209,496. The Company had not recorded a liability with respect to the guarantee obligation as of June 30, 2023, as the Company concluded that payment under the lease guarantee was not probable.
Litigation
In the normal course of business, the Company is party to litigation and claims from time to time. The Company maintains insurance to cover certain litigation and claims.
Note 11: Segment Reporting
An operating segment is defined as a component of an enterprise for which discrete financial information is available and is reviewed regularly by the Chief Operating Decision Maker (“CODM”) to evaluate performance and make operating decisions. The Company has identified its CODM as the Chief Executive Officer.
The Company has two operating business segments and one non-operating business segment. The Corporate Clinics segment is composed of the operating activities of the company-owned or managed clinics. As of June 30, 2023, the Company operated or managed 134 clinics under this segment. The Franchise Operations segment is composed of the operating activities of the franchise business unit. As of June 30, 2023, the franchise system consisted of 756 clinics in operation. Corporate is a non-operating segment that develops and implements strategic initiatives and supports the Company’s two operating business segments by centralizing key administrative functions such as finance and treasury, information technology, insurance and risk management, legal and human resources. Corporate also provides the necessary administrative functions to support the Company as a publicly-traded company. A portion of the expenses incurred by Corporate are allocated to the operating segments.
The tables below present financial information for the Company’s two operating business segments.
33
Three Months EndedSix Months Ended
June 30,June 30,
2023202220232022
Revenues:(as restated)(as restated)
Corporate clinics$17,802,838 $14,492,972 $34,930,795 $27,099,971 
Franchise operations11,504,346 10,394,393 22,677,210 20,024,145 
Total revenues$29,307,184 $24,887,365 $57,608,005 $47,124,116 
Depreciation and amortization:
Corporate clinics2,032,666 1,191,694 3,959,758 2,275,370 
Franchise operations207,717 186,247 406,690 359,735 
Corporate administration88,884 83,929 177,874 163,422 
Total depreciation and amortization$2,329,267 $1,461,870 $4,544,322 $2,798,527 
Segment operating income (loss):
Corporate clinics$21,790 $551,223 $(400,263)$405,680 
Franchise operations4,232,245 2,162,769 8,774,144 6,411,204 
Total segment operating income$4,254,035 $2,713,992 $8,373,881 $6,816,884 
Reconciliation of total segment operating income to consolidated earnings before income taxes:
Total segment operating income$4,254,035 $2,713,992 $8,373,881 $6,816,884 
Unallocated corporate(4,628,589)(4,044,458)(9,401,544)(8,186,058)
Consolidated income from operations(374,554)(1,330,466)(1,027,663)(1,369,174)
Other income (expense), net(106,520)(19,286)3,714,642 (35,434)
(Loss) income before income tax expense$(481,074)$(1,349,752)$2,686,979 $(1,404,608)
Segment assets:June 30,
2023		December 31,
2022
Corporate clinics$56,791,939 $56,008,234 
Franchise operations13,716,15712,360,878
Total segment assets70,508,09668,369,112
Unallocated cash and cash equivalents and restricted cash14,451,34610,550,417
Unallocated property and equipment734,432915,216
Other unallocated assets13,512,72313,655,632
Total assets$99,206,597 $93,490,377 
“Unallocated cash and cash equivalents and restricted cash” relates primarily to corporate cash and cash equivalents and restricted cash (see Note 1), “unallocated property and equipment” relates primarily to corporate fixed assets, and “other unallocated assets” relates primarily to deposits, prepaid and other assets.
Note 12: Employee Retention Credit
The employee retention credit ("ERC"), as originally enacted through the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020, is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The Disaster Tax Relief Act, enacted on December 27, 2020, extended the ERC for qualified wages paid from January 1, 2021 to June 30, 2021, and the credit was
34
increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the ERC through December 31, 2021.

In October 2022, the Company filed an application with the IRS for the ERC. Employers are eligible for the credit if they experienced full or partial suspension or modification of operations during any calendar quarter because of governmental orders due to the pandemic or a significant decline in gross receipts based on a comparison of quarterly revenue results for 2020 and/or 2021 with the comparable quarter in 2019. The Company’s ERC application was equal to 70% of qualified wages paid to employees during the period from January 1, 2021 to June 30, 2021 for a maximum quarterly credit of $7,000 per employee. In March 2023, the Company received notice and refunds from the IRS related to the overpayment of Federal Employment Tax plus interest in the amount of $4.8 million related to the ERC application. The $4.8 million ERC is subject to a 20% consulting fee. The Company's eligibility remains subject to audit by the IRS for a period of five years.

Since there are no generally accepted accounting principles for for-profit business entities that receive government assistance that is not in the form of a loan, an income tax credit or revenue from a contract with a customer, we determined the appropriate accounting treatment by analogy to other guidance. We accounted for the ERC by analogy to International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, of International Financial Reporting Standards (IFRS).

Under an IAS 20 analogy, a business entity would recognize the ERC on a systematic basis over the periods in which the entity recognizes the payroll expenses for which the grant (i.e., tax credit) is intended to compensate when there is reasonable assurance (i.e., it is probable) that the entity will comply with any conditions attached to the grant and the grant (i.e., tax credit) will be received.

We have accounted for the $3.8 million ERC, net of the consulting fee, for the six months ended June 30, 2023 as other income on the Statement of Income when the Company was reasonably assured that the Company met all requirements of the ERC and the grant would be received. The ERC refund is not taxable; however, the credit is subject to expense disallowance rules which increased income tax expense as a discrete item by $0.9 million, net of the consulting expense deduction, for the six months ended June 30, 2023.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Amended Annual Report on Form 10-K/A.
Forward-Looking Statements

This Quarterly Report on Form 10-Q, especially in this Management’s Discussion and Analysis or MD&A, contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included or incorporated in this Form 10-Q could be deemed forward-looking statements, particularly statements about our plans, strategies and prospects under the headings “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intend,” “seek,” “strive,” or the negative of these terms, “mission,” “goal,” “objective,” or “strategy,” or other comparable terminology. All forward-looking statements in this Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions, and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations as described from time to time in our SEC reports, including those risks outlined under “Risk Factors” which are contained in Part I, Item 1A of our Form 10-K/A for the year ended December 31, 2022 and in Part II, Item 1A of this or any subsequent quarterly reports on Form 10-Q. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Form 10-Q. You should carefully consider the trends, risks and uncertainties described below and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. We undertake no obligation to update or revise publicly any forward-looking statements, other than in accordance with legal and regulatory obligations. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. Some of the important factors
35
that could cause our actual results to differ materially from those projected in any forward-looking statements include, but are not limited to, the following:
•the nationwide labor shortage has negatively impacted our ability to recruit chiropractors and other qualified personnel, which may limit our growth strategy, and the measures we have taken in response to the labor shortage have reduced our net revenues;

•inflation, exacerbated by COVID-19 and the Ukraine War, has led to increased labor costs and interest rates and may lead to reduced discretionary spending, all of which may negatively impact our business;

•the COVID-19 pandemic has caused significant disruption to our operations and may continue to impact our business, key financial and operating metrics, and results of operations in numerous ways that remain unpredictable; future widespread outbreaks of contagious disease could similarly disrupt our business;
•we may not be able to successfully implement our growth strategy if we or our franchisees are unable to locate and secure appropriate sites for clinic locations, obtain favorable lease terms, and attract patients to our clinics;
•we have limited experience operating company-owned or managed clinics in those geographic areas where we currently have few or no clinics, and we may not be able to duplicate the success of some of our franchisees;
•we may not be able to acquire operating clinics from existing franchisees or develop company-owned or managed clinics on attractive terms;
•short-selling strategies and negative opinions posted on the internet may drive down the market price of our common stock and could result in class action lawsuits;
•we have identified material weaknesses in our internal controls over financial reporting and we may fail to remediate material weaknesses in our internal controls over financial reporting or may otherwise be unable to maintain an effective system of internal control over financial reporting, which might negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence;
•we may fail to successfully design and maintain our proprietary and third-party management information systems or implement new systems;
•we have restated our prior consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on our stock price;
•we may fail to properly maintain the integrity of our data or to strategically implement, upgrade or consolidate existing information systems;
• franchised clinic acquisitions that we make could disrupt our business and harm our financial condition if we cannot continue their operational success or successfully integrate them;
•we may not be able to continue to sell franchises to qualified franchisees, and our franchisees may not succeed in developing profitable territories and clinics;
•new clinics may not reach the point of profitability, and we may not be able to maintain or improve revenues and franchise fees from existing franchised clinics;
•the chiropractic industry is highly competitive, with many well-established independent competitors, which could prevent us from increasing our market share or result in reduction in our market share;
•state administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize our business model;
•expected new federal regulations and state laws and regulations regarding joint employer responsibility could negatively impact the franchise business model, increasing our potential liability for employment law violations by our franchisees and the likelihood that we may be required to participate in collective bargaining with our franchisees’ employees;
36
•an increased regulatory focus on the establishment of fair franchise practices could increase our risk of liability in disputes with franchisees and the risk of enforcement actions and penalties;
•adverse developments affecting institutions, including bank failures, could adversely affect our liquidity and financial performance;
•negative publicity or damage to our reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models, could adversely impact our operations and financial position;
•our IT security systems and those of our third-party service providers (as recently experienced by one of our marketing vendors) may be breached, and we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract and retain patients;
•new SEC regulations governing disclosure about risk management, strategy and governance regarding cybersecurity risks and new requirements for reporting of cybersecurity incidents may increase our compliance costs;
•legislation, regulations, as well as new medical procedures and techniques, could reduce or eliminate our competitive advantages; and
•the delayed filing of our quarterly report has made us currently ineligible to use a registration statement on Form S-3 to register the offer and sale of securities, which could adversely affect our ability to raise future capital or complete acquisitions.
Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the Securities and Exchange Commission. Any forward-looking statements in this report should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others.
Overview
Our principal business is to develop, own, operate, support and manage chiropractic clinics through direct ownership, management arrangements, franchising and regional developers throughout the United States.
We seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad.
Key Performance Measures. We receive monthly performance reports from our system and our clinics which include key performance indicators per clinic including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage, and membership attrition. In addition, we review monthly reporting related to system-wide sales, clinic openings, clinic license sales, adjusted EBITDA, and various earnings metrics in the aggregate and per clinic. We believe these indicators provide us with useful data with which to measure our performance and to measure our franchisees’ and clinics’ performance. Comp Sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed. System-wide sales include sales at all clinics, whether operated by us or by franchisees. While franchised clinic sales are not recorded as revenues by us, management believes the information is important in understanding the overall brand’s financial performance, because these sales are the basis on which we calculate and record royalty fees and are indicative of the financial health of the franchisee base. Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses, stock-based compensation expense, bargain purchase gain, and (gain) loss on disposition or impairment. There was no bargain purchase gain for the three and six months ended June 30, 2023 and 2022.
Key Clinic Development Trends. As of June 30, 2023, we and our franchisees operated or managed 890 clinics, of which 756 were operated or managed by franchisees and 134 were operated as company-owned or managed clinics. Of the 134 company-owned or managed clinics, 63 were constructed and developed by us, and 71 were acquired from franchisees.
Our current strategy is to grow through the sale and development of additional franchises, build upon our regional developer strategy, and continue to expand our corporate clinic portfolio within clustered locations. The number of franchise licenses sold for the year ended December 31, 2022 was 75, compared with 156 and 121 licenses for the years ended December 31, 2021 and
37
2020, respectively. We ended the first half of 2023 with 17 regional developers who were responsible for 58% of the 38 licenses sold during the period. This strong result reflects the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country.
In addition, we believe that we can accelerate the development of, and revenue generation from, company-owned or managed clinics through the accelerated development of greenfield units and the further selective acquisition of existing franchised clinics. We will seek to acquire existing franchised clinics that meet our criteria for demographics, site attractiveness, proximity to other clinics and additional suitability factors. During the quarter ended June 30, 2023, we opened three greenfield clinics.
We believe that The Joint has a sound concept, which was further validated through its resiliency during the pandemic and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness. These trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model to produce a combination that benefits the consumer and the service provider alike. We believe that these forces create an important opportunity to accelerate the growth of our network.
Recent Events

Recent events that may impact our business include unfavorable global economic or political conditions, such as a resurgence of COVID-19, the Ukraine War, labor shortages, and inflation and other cost increases. We anticipate that 2023 will continue to be a volatile macroeconomic environment. As of the date of this Quarterly Report on Form 10-Q, we have not experienced a significant negative impact on our revenues and profitability due to the direct impact of the pandemic, and the impact of Covid-19 in general on the business environment has largely moderated. However, there still remains uncertainty around the pandemic, including its effect on labor or other macroeconomic factors and the spread of new Covid-19 variants and resurgences.

The primary inflationary factor affecting our operations is labor costs. For the three and six months ended June 30, 2023, company-owned or managed clinics were negatively impacted by labor shortages and wage increases, which increased our general and administrative expenses. Further, should we fail to continue to increase our wages competitively in response to increasing wage rates, the quality of our workforce could decline, causing our patient service to suffer. We expect elevated levels of cost inflation to persist in 2023, although at lower levels than experienced in 2022. While the effects of inflation on our labor costs have been partially mitigated by pricing actions we have taken in response, there can be no assurance that we will be able to continue to take such pricing actions. A continued increase in labor costs could have an adverse effect on our operating costs, financial condition and results of operations.

Also, the Ukraine War and the sanctions imposed on Russia in response to this conflict have increased global economic and political uncertainty. In addition, the increase in interest rates and the expectation that interest rates will continue to rise may adversely affect patients' financial conditions, resulting in reduced spending on our services. While the impact of these factors continues to remain uncertain, we will continue to evaluate the extent to which these factors will impact our business, financial condition, or results of operations. These and other uncertainties with respect to these recent events could result in changes to our current expectations.
38
Other Significant Events and/or Recent Developments
For the three months ended June 30, 2023, compared to the prior year period:
•System-wide comp Sales of clinics that have been open for at least 13 full months increased 5.0%.

•System-wide comp Sales for mature clinics open 48 months or more decreased 1.0%.

•System-wide sales for all clinics open for any amount of time grew 13.3%.

On June 15, 2023, we entered into an agreement under which we repurchased the right to develop franchises in various counties in Wisconsin. The total consideration for the transaction was $1.0 million. We carried an upfront regional developer fee liability balance associated with this transaction of $0.3 million, representing the unrecognized fee collected upon the execution of the regional developer agreement. We accounted for the termination of development rights associated with unsold or undeveloped franchises as a cancellation, and the associated upfront regional developer fee liability was netted against the aggregate purchase price. We recognized the net amount of $0.7 million as a general and administrative expense on June 15, 2023.
On May 22, 2023, we entered into an Asset and Franchise Purchase Agreement under which we repurchased from the sellers three operating franchised clinics in California. We operate the franchises as company-managed clinics. The total purchase price for the transaction was $1,188,764, less $28,997 of net deferred revenue, resulting in total purchase consideration of $1,159,767. Based on the terms of the purchase agreement, the acquisition has been treated as an asset purchase.
For the three months ended June 30, 2023, we constructed and developed three new corporate clinics.
39
Factors Affecting Our Performance
Our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns, such as a resurgence of COVID-19.
Critical Accounting Estimates
There were no changes in our critical accounting estimates during the six months ended June 30, 2023 from those set forth in “Significant Accounting Policies and Estimates” in our Form 10-K/A for the year ended December 31, 2022.

Restatement of Previously Issued Consolidated Financial Statements

The Company concluded that the Company’s previously issued financial statements for the years ended December 31, 2022 and 2021 and interim periods, except for the three month periods ended March 31, 2023 and 2022, should be restated to correct historical errors related principally to the accounting for the purchase of reacquired Regional Developer Rights and impact of certain transfer pricing adjustments for the Company’s consolidated VIEs. The discussion of financial results presented herein is reflective of the restatement adjustments for 2022 and 2021.

Default Under Credit Agreement

On September 8, 2023, JP Morgan Chase waived, on a one-time only basis, a default that occurred under the Credit Agreement. The default occurred as of the close of business on September 6, 2023. The default resulted from the Company’s inability to deliver in a timely manner the financial statements in this Quarterly Report on Form 10-Q. The Company’s inability to produce and file this Quarterly Report on Form 10-Q in a timely manner (which filing constitutes delivery to JP Morgan Chase of the Company’s financial statements) was the result of the discovery of errors in the US GAAP accounting treatment for re-acquired regional developer rights and for transfer pricing for its variable interest entities. JP Morgan Chase waived this default until September 30, 2023. The filing of this Quarterly Report on Form 10-Q prior to September 30, 2023 cures the default.

Results of Operations
The following discussion and analysis of our financial results encompasses our consolidated results and results of our two business segments: Corporate Clinics and Franchise Operations. 
Total Revenues - three months ended June 30, 2023 compared with three months ended June 30, 2022
Components of revenues were as follows:
Three Months Ended
June 30,
20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Revenues:
Revenues from company-owned or managed clinics$17,802,838 $14,492,972 $3,309,866 22.8 %
Royalty fees7,172,159 6,411,214 $760,945 11.9 %
Franchise fees671,368 686,886 $(15,518)(2.3)%
Advertising fund revenue2,041,050 1,825,757 $215,293 11.8 %
IT related income and software fees1,234,812 1,099,981 $134,831 12.3 %
Other revenues384,957 370,555 $14,402 3.9 %
Total revenues$29,307,184 $24,887,365 $4,419,819 17.8 %
Consolidated Results
40
Total revenues increased by $4.4 million, primarily due to the continued expansion and revenue growth of our franchise base and the continued revenue growth and expansion of our company-owned or managed clinics portfolio.
Corporate Clinics
Revenues from company-owned or managed clinics increased, primarily due to the expansion of our corporate-owned or managed clinics portfolio, as well as due to improved same-store sales growth of newer clinics. As of June 30, 2023 and 2022, there were 134 and 107 company-owned or managed clinics in operation, respectively.
Franchise Operations
•Royalty fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period, along with continued sales growth in existing franchised clinics. As of June 30, 2023 and 2022, there were 756 and 662 franchised clinics in operation, respectively.
•Franchise fees remained relatively flat due to a slight decrease in executed franchise agreements in the current quarter period compared to the prior period, as these fees are recognized ratably over the term of the respective franchise agreement, partially offset by the impact of greater accelerated revenue recognition resulting from the terminated franchise license agreements in the current quarter period compared to the prior period.
•Software fees revenue increased due to an increase in our franchised clinic base and the related revenue recognition over the term of the franchise agreement as described above.
•Other revenues primarily consisted of merchant income associated with credit card transactions.
Total Revenues - six months ended June 30, 2023 compared with six months ended June 30, 2022
Components of revenues were as follows:
Six Months Ended
June 30,
20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Revenues:
Revenues from company-owned or managed clinics$34,930,795 $27,099,971 $7,830,824 28.9 %
Royalty fees14,038,182 12,420,146 $1,618,036 13.0 %
Franchise fees1,425,794 1,327,851 $97,943 7.4 %
Advertising fund revenue3,993,455 3,536,474 $456,981 12.9 %
IT related income and software fees2,444,817 2,056,979 $387,838 18.9 %
Other revenues774,962 682,695 $92,267 13.5 %
Total revenues$57,608,005 $47,124,116 $10,483,889 22.2 %
Consolidated Results
Total revenues increased by $10.5 million, primarily due to the continued expansion and revenue growth of our franchise base and of our company-owned or managed clinics portfolio.
Corporate Clinics
Revenues from company-owned or managed clinics increased, primarily due to the expansion of our corporate-owned or managed clinics portfolio, as well as due to improved same-store sales growth in newer clinics. As of June 30, 2023 and 2022, there were 134 and 107 company-owned or managed clinics in operation, respectively.
Franchise Operations
41
•Royalty fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period, along with continued sales growth in existing franchised clinics. As of June 30, 2023 and 2022, there were 756 and 662 franchised clinics in operation, respectively.
•Franchise fees increased primarily due to the increase in number of franchise licenses from the prior period in addition to accelerated revenue recognition resulting from the terminated franchise license agreements in the current year period compared to the prior period.
•Software fees revenue increased due to an increase in our franchised clinic base and the related revenue recognition over the term of the franchise agreement as described above.
•Other revenues primarily consisted of merchant income associated with credit card transactions.
Cost of Revenues20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Three Months Ended June 30,2,595,512 2,257,092 $338,420 15.0 %
Six Months Ended June 30,5,070,197 4,368,076 $702,121 16.1 %
For the three months ended June 30, 2023, as compared with the three months ended June 30, 2022, the total cost of revenues increased primarily due to an increase in regional developer royalties and sales commissions of $0.3 million. For the six months ended June 30, 2023, as compared with the six months ended June 30, 2022, the total cost of revenues increased primarily due to an increase in regional developer royalties and sales commissions of $0.7 million.
Selling and Marketing Expenses
Selling and Marketing Expenses20232022Change from
Prior Year		Percent Change
from Prior Year
Three Months Ended June 30,4,707,818 3,839,724 $868,094 22.6 %
Six Months Ended June 30,8,868,062 7,127,212 $1,740,850 24.4 %

Selling and marketing expenses increased for the three and six months ended June 30, 2023, as compared to the three and six months ended June 30, 2022, driven by an increase in advertising fund expenditures from a larger franchise base and an increase in local marketing expenditures by the company-owned or managed clinics.
Depreciation and Amortization Expenses
Depreciation and Amortization Expenses20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Three Months Ended June 30,2,329,267 1,461,870 $867,397 59.3 %
Six Months Ended June 30,4,544,322 2,798,527 $1,745,795 62.4 %
Depreciation and amortization expenses increased for the three and six months ended June 30, 2023, as compared to the three and six months ended June 30, 2022, driven by the depreciation and amortization expenses associated with the expansion of our corporate-owned or managed clinics portfolio in 2022 and 2023.
42
General and Administrative Expenses
General and Administrative Expenses20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Three Months Ended June 30,19,904,796 18,570,301 $1,334,495 7.2 %
Six Months Ended June 30,39,943,272 34,103,726 $5,839,546 17.1 %
General and administrative expenses increased for the three months ended June 30, 2023, as compared to the three months ended June 30, 2022, primarily due to the increases in the following to support continued clinic count and revenue growth in both operating segments: (i) payroll and related expenses of $1.8 million, (ii) utilities and facilities expenses in the corporate clinic segment of $0.4 million, (iii) software and maintenance expense of $0.2 million, and (iv) professional and advisory fees of $0.2 million partially offset by a decrease in reacquisition of regional developer rights of $1.3 million. General and administrative expenses increased for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022, primarily due to the increases in the following to support continued clinic count and revenue growth in both operating segments: (i) payroll and related expenses of $5.5 million, (ii) utilities and facilities expenses in the corporate clinic segment of $0.9 million, (iii) professional and advisory fees of $0.3 million, (iv) software and maintenance expense of $0.3 million, and (v) general overhead and administrative expenses of $0.2 million partially offset by a decrease in reacquisition of regional developer rights of $1.4 million. As a percentage of revenue, general and administrative expenses during the six months ended June 30, 2023 and 2022 were 69% and 72%, respectively.
Income from Operations - three months ended June 30, 2023 compared with three months ended June 30, 2022
Three Months Ended June 30,20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Loss from Operations(374,554)(1,330,466)$955,912 (71.8)%
Consolidated Results
Consolidated loss from operations decreased by $1.0 million for the three months ended June 30, 2023 compared with the three months ended June 30, 2022, primarily due to the increased expenses in the corporate clinics and unallocated corporate segments discussed below.
Corporate Clinics
Our corporate clinics segment had loss from operations of $21,790 for the three months ended June 30, 2023, a decrease of $0.5 million compared to income from operations of $0.6 million for the prior year period. The decrease was primarily due to:
•A $3.8 million increase in operating expenses due to the increases in the following: (i) payroll-related expenses of $1.5 million due to a higher head count to support the expansion of our corporate clinic portfolio and general wage increases to remain competitive in the current labor market, (ii) depreciation and amortization expense associated with the expansion of our corporate-owned or managed clinics portfolio in 2022 and 2023 of $0.8 million, (iii) selling and marketing expenses due to increased local marketing expenditures by the company-owned or managed clinics of $0.9 million, and (iv) general overhead and administrative expenses to support the expansion of our corporate clinic portfolio of $0.6 million; partially offset by
•An increase in revenues of $3.3 million from company-owned or managed clinics.
Franchise Operations
Our franchise operations segment had income from operations of $4.2 million for the three months ended June 30, 2023, an increase of $2.1 million, compared to income from operations of $2.2 million for the prior year period. This increase was primarily due to:
43
•An increase of $1.1 million in total revenues; plus
•A decrease of general and administrative expenses related to reacquired regional developer rights of $1.3 million; partially offset by
•An increase of $0.3 million in cost of revenues primarily due to an increase in regional developer royalties and an increase of $0.1 million in operating expenses due to an increase in payroll-related expenses.
Unallocated Corporate
Unallocated corporate expenses for the three months ended June 30, 2023 increased by $0.6 million compared to the prior year period, primarily due to the increase in general and administrative expenses of $0.6 million.
Income from Operations - six months ended June 30, 2023 compared with six months ended June 30, 2022
Six Months Ended June 30,20232022Change from
Prior Year		Percent Change
from Prior Year
(as restated)
Loss from Operations(1,027,663)(1,369,174)$341,511 (24.9)%
Consolidated Results
Consolidated loss from operations decreased by $0.3 million for the six months ended June 30, 2023 compared with the six months ended June 30, 2022, primarily due to the increased expenses in the corporate clinics and unallocated corporate segments discussed below.
Corporate Clinics
Our corporate clinics segment had a loss from operations of $0.4 million for the six months ended June 30, 2023, a decrease of $0.8 million compared to income from operations of $0.4 million for the prior year period. The decrease was primarily due to:
•A $8.6 million increase in operating expenses due to the increases in the following: (i) payroll-related expenses of $4.2 million due to a higher head count to support the expansion of our corporate clinic portfolio and general wage increases to remain competitive in the current labor market, (ii) depreciation and amortization expense associated with the expansion of our corporate-owned or managed clinics portfolio in 2022 and 2023 of $1.7 million, (iii) selling and marketing expenses due to increased local marketing expenditures by the company-owned or managed clinics of $1.4 million, and (iv) general overhead and administrative expenses to support the expansion of our corporate clinic portfolio of $1.3 million; partially offset by
•An increase in revenues of $7.8 million from company-owned or managed clinics.
Franchise Operations
Our franchise operations segment had income from operations of $8.8 million for the six months ended June 30, 2023, an increase of $2.4 million, compared to income from operations of $6.4 million for the prior year period. This increase was primarily due to:
•An increase of $2.7 million in total revenues; plus
•A decrease of general and administrative expenses related to reacquired regional developer rights of $1.4 million; partially offset by; partially offset by
•An increase of $0.7 million in cost of revenues primarily due to an increase in regional developer royalties and an increase of $1.0 million in operating expenses, primarily due to an increase in: (i) selling and marketing expenses resulting from a larger franchise base of $0.3 million, (ii) payroll-related expenses of $0.5 million, and (iii) travel-related expenses of $0.1 million resulting from supporting franchise base regions previously supported by regional developers.
44
Unallocated Corporate
Unallocated corporate expenses for the six months ended June 30, 2023 increased by $1.2 million compared to the prior year period, primarily due to the increases in payroll-related expenses of $0.9 million and increases in professional and advisory fees of $0.3 million.
Other Income (Expense), Net
Three Months Ended June 30,20232022Change from
Prior Year		Percent Change
from Prior Year
Other income (expense), net(106,520)(19,286)$(87,234)(452.3)%
Other income (expenses), net decreased during the three months ended June 30, 2023 compared to the three months ended June 30, 2022, primarily due to the reduction of the estimated employee retention credits ("ERC") of $92,000 and an increase in interest expense of $33,000. These negative impacts were partially offset by an increase in interest income of $54,000.
Six Months Ended June 30,20232022Change from
Prior Year		Percent Change
from Prior Year
Other income (expense), net3,714,642 (35,434)$3,750,076 10,583.3 %
Other income (expenses), net increased during the six months ended June 30, 2023 compared to the six months ended June 30, 2022, primarily due to the recognition and receipt of the $3.8 million of ERC, net of the consulting fee, in the first quarter of 2023, partially offset by net interest expense of $0.1 million.
Non-GAAP Financial Measures
The table below reconciles net income (loss) to Adjusted EBITDA for the three and six months ended June 30, 2023 and 2022.
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
(as restated)(as restated)
Non-GAAP Financial Data:
   Net (loss) income$(320,489)$(871,868)$2,005,675 $(867,648)
   Net interest expense14,937 19,286 64,661 35,433 
   Depreciation and amortization expense2,329,267 1,461,870 4,544,322 2,798,527 
   Tax expense (benefit)(160,585)(477,884)681,304 (536,960)
      EBITDA1,863,130 131,404 7,295,962 1,429,352 
   Stock compensation expense417,017 340,191 683,227 663,747 
   Acquisition related expenses716,299 2,074,153 857,992 2,228,668 
   Loss on disposition or impairment144,345 88,844 209,815 95,749 
Other (income), net91,583 — (3,779,304)— 
      Adjusted EBITDA$3,232,374 $2,634,592 $5,267,692 $4,417,516 
Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses, stock-based compensation expense, bargain purchase gain, and (gain) loss on disposition or impairment and other income related to the ERC. There was no bargain purchase gain for the three and six months ended June 30, 2023 and 2022. We have provided Adjusted EBITDA because it is a non-GAAP measure of financial performance commonly used for comparing companies in our industry. You should not consider Adjusted EBITDA as a substitute for operating profit or as an indicator of our
45
operating performance or as an alternative to cash flows from operating activities as a measure of liquidity. We may calculate Adjusted EBITDA differently from other companies.

We believe that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other outpatient medical clinics, which may present similar non-GAAP financial measures to investors. In addition, you should be aware when evaluating Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate Adjusted EBITDA in the same manner.
Liquidity and Capital Resources
As of June 30, 2023, we had unrestricted cash and short-term bank deposits of $13.6 million and $18 million of available capacity under the Revolver. While the pandemic and the Ukraine War create potential liquidity risks, as discussed further below, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next twelve months.

While the interruptions, delays and/or cost increases resulting from the pandemic, political instability or geopolitical tensions, such as the Ukraine War, economic weakness, inflationary pressures or other factors have created uncertainty as to general economic conditions for 2023 and beyond, as of the date of this report, we believe we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business. For the remainder of 2023, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change. Our long-term capital requirements, primarily for acquisitions and other corporate initiatives, could be dependent on our ability to access additional funds through the debt and/or equity markets. If the equity or debt markets continue to deteriorate or do not improve, including as a result of economic weakness, a resurgence of COVID-19, political unrest or war, including the Ukraine War, or any other reason, it may make any necessary equity or debt financing more difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, it may be more costly or more dilutive. From time to time, we consider and evaluate transactions related to our portfolio and capital structure, including debt financings, equity issuances, purchases and sales of assets, and other transactions. Given the ongoing uncertainties described above, the levels of our cash flows from operations for 2023 may be impacted. There can be no assurance that we will be able to generate sufficient cash flows or obtain the capital necessary to meet our short and long-term capital requirements.
Analysis of Cash Flows
Net cash provided by operating activities increased by $8.7 million to $7.5 million for the six months ended June 30, 2023, compared to $(1.2) million for the six months ended June 30, 2022. The increase was primarily attributable to an increase in revenue over the prior year period and the receipt of the $4.8 million ERC, which was partially offset by an increase in general and administrative expenses over the prior year period.
Net cash used in investing activities was $3.8 million and $8.8 million for the six months ended June 30, 2023 and 2022, respectively. For the six months ended June 30, 2023, this included acquisitions of $1.1 million, and purchases of property and equipment of $2.7 million. For the six months ended June 30, 2022, this included acquisitions of $5.6 million, and the purchases of property and equipment of $3.2 million.
Net cash provided by financing activities for the six months ended June 30, 2023 was $0.2 million, compared to less than $100 thousand for the six months ended June 30, 2022. For the six months ended June 30, 2023, this included the proceeds from the exercise of stock options of $0.2 million.
Recent Accounting Pronouncements
See Note 1, Nature of Operations and Summary of Significant Accounting Policies, to our condensed consolidated financial statements included in this report for information regarding recently issued accounting pronouncements that may impact our financial statements.
Off-Balance Sheet Arrangements
46
During the six months ended June 30, 2023, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of June 30, 2023, there were no material changes to the quantitative and qualitative disclosures about market risk appearing in Part II, Item 7(a), “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K/A for the year ended December 31, 2022.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures were designed to provide reasonable assurance of achieving such objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2023, our management concluded that as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

Our management determined that the material weaknesses disclosed for the year ended December 31, 2022 and 2021 in its internal control over financial reporting continue to exist at June 30, 2023, specifically:

We failed to properly design controls to appropriately determine the proper treatment of complex accounting areas, including income taxes, revenue recognition and asset acquisition transactions.

Remediation Plan for Existing Material Weaknesses

We are in the process of and continue to focus on implementing measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include modifying internal controls to address completeness of documentation on uncertain tax positions, revenue and acquisition related transactions and adoptions of the appropriate respective accounting standards, specifically through the utilization of subject matter experts to review conclusions over complex accounting policies. While we expect that our remediation actions over the design of our affected controls for the material weakness will be completed during fiscal 2023, the material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
Changes in Internal Control over Financial Reporting

Except as described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, we are a party to litigation from time to time. We maintain insurance to cover certain litigation and claims.
ITEM 1A. RISK FACTORS
47

We documented our risk factors in Item 1A of Part I of our Form 10-K/A for the year ended December 31, 2022. There have been no material changes to our risk factors since the filing of that report, except for the addition or modification of the following risk factors:

In RISKS RELATED TO OPERATING OUR BUSINESS:

Inflation, exacerbated by COVID-19 and the Ukraine War, has led to increased labor costs and interest rates and may lead to reduced discretionary spending, all of which may negatively impact our business.

The primary inflationary factor affecting our operations is labor costs. During 2022 and 2023, company-owned or managed clinics were negatively impacted by wage increases, which increased our general and administrative expenses and decreased profitability. A significant number of our clinic service personnel are paid at rates related to the applicable minimum wage, and increases in the minimum wage could increase our labor costs. As of January 1, 2023, the minimum wage increased in a number of states, the District of Columbia and local municipalities, with many of these wage increases triggered automatically by increases in the cost of living due to high inflation. Such wage increases likely will further increase our general and administrative expenses in the affected jurisdictions. A continued increase in labor costs is likely to continue to have an adverse impact on profitability and may result in additional price increases to offset their impact. Further, should we fail to continue to increase our wages competitively in response to any continued increase in wage rates, the quality of our workforce could decline, causing our patient services to suffer.

In addition to relief and recovery, our services emphasize preventive and maintenance care, which is generally not a medical necessity, and may be viewed as a discretionary medical expenditure. Discretionary spending is negatively impacted by, among other things, those factors disclosed in our Form 10-K/A for the year ended December 31, 2022 under the caption “Recent Events” in Management’s Discussion and Analysis of Financial Condition and Results of Operations -- unfavorable global economic or political conditions, such as the recent COVID-19 pandemic, the Ukraine War, inflation and other cost increases, and increases in interest rates. As further disclosed under the aforementioned caption, we anticipate that fiscal 2023 will continue to be a volatile macroeconomic environment and expect elevated levels of cost inflation to persist for 2023. Reductions in discretionary spending may adversely impact our business, financial condition, or results of operations. Rising interest rates also will make it more expensive for potential franchisees to finance new clinic acquisitions and thus may reduce the pool of available franchisees, which also could adversely impact our business. Borrowings under our credit facility bear interest at rates tied to certain benchmark interest rates. Increases in the federal funds rate has caused these benchmark rates to increase, and additional increases are likely to further increase such benchmark rates. Higher rates increase our borrowing costs and may reduce the amounts available under our credit facility for our corporate needs, including working capital, capital expenditures and acquisitions.

In the event that a further deterioration of economic conditions causes a significant decrease in demand for our services, this could negatively impact our ability to meet the financial covenants in our credit facility, although we were in compliance as of June 30, 2023. Furthermore, a deterioration of equity and credit markets may make other debt or equity financing difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, may be more costly or more dilutive. If we are unable to access our credit facility as a result of noncompliance with its covenants or are unable to obtain other debt or equity financing, this could limit our opportunity to acquire more clinics and regional developer rights and to pursue other corporate initiatives.

In FINANCIAL RISK FACTORS:

We maintain cash deposits in banks in excess of federally-insured limits. Adverse developments affecting financial institutions, including bank failures, could adversely affect our liquidity and financial performance.

We regularly maintain cash deposits in Federal Deposit Insurance Corporation (“FDIC”) insured banks that exceed the FDIC insurance limits. Bank failures, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to liquidity constraints. For example, on March 10, 2023, Silicon Valley Bank failed and was taken into receivership by the FDIC. Although we did not have any funds in Silicon Valley Bank or other institutions that have been closed, we cannot guarantee that the banks or other financial institutions that hold our funds will not experience similar issues. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S., or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis.
48

In RISKS RELATED TO OTHER LEGAL AND REGULATORY MATTERS:

We conduct business in a heavily regulated industry, and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations.

We, our franchisees and the chiropractor-owned PCs to which we and our franchisees provide management services are subject to extensive federal, state and local laws, rules and regulations, including: (i) federal and state laws governing the franchisor-franchisee relationship; (ii) state regulations on the practice of chiropractic; (iii) federal and state laws governing the collection, dissemination, use, security and confidentiality of sensitive personal information; (iv) federal and state laws which contain anti-kickback and fee-splitting provisions and restrictions on referrals; (v) the federal Fair Debt Collection Practices Act and similar state laws that restrict the methods that we and third-party collection companies may use to contact and seek payment from patients regarding past due accounts; (vi) prepayment for chiropractic services; and (vii) federal and state labor laws, including wage and hour laws.

Some state regulations concerning the practice of chiropractic could limit the use of our business model or certain of our business practices in certain states, which may make expanding into those states less attractive. For example, some states prohibit payment in advance for chiropractic services. This has the effect of limiting or prohibiting the use of our membership model in any such states, given that our membership model provides for the payment in advance of a monthly membership fee prior to receipt of services and without regard to whether services are actually provided. We recently elected not to offer franchises in South Dakota and Wyoming because of such a prohibition.

Many of the above laws, rules and regulations applicable to us, our franchisees and our affiliated PCs are ambiguous, have not been definitively interpreted by courts or regulatory authorities and vary from jurisdiction to jurisdiction. Accordingly, we may not be able to predict how these laws and regulations will be interpreted or applied by courts and regulatory authorities, and some of our activities could be challenged. In addition, we must consistently monitor changes in the laws and regulations that govern our operations. Furthermore, a review of our business by judicial, law enforcement or regulatory authorities could result in a determination that could adversely affect our operations. Although we have tried to structure our business and contractual relationships in compliance with these laws, rules and regulations in all material respects, if any aspect of our operations were found to violate applicable laws, rules or regulations, we could be subject to significant fines or other penalties, required to cease operations in a particular jurisdiction, prevented from commencing operations in a particular state or otherwise be required to revise the structure of our business or legal arrangements. Our efforts to comply with these laws, rules and regulations may impose significant costs and burdens, and failure to comply with these laws, rules and regulations may result in fines or other charges being imposed on us.

In RISKS RELATED TO INFORMATION TECHNOLOGY, CYBERSECURITY AND DATA PRIVACY:

New SEC regulations governing disclosure about risk management, strategy and governance regarding cybersecurity risks and new requirements for reporting of cybersecurity incidents may increase our compliance costs.

The SEC recently adopted a rule, “Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure,” that enhances and standardizes disclosures regarding cybersecurity risk management and governance, as well as material cybersecurity incidents. Under this new rule, public companies will now be required to make annual disclosures describing their processes for identifying and managing material cybersecurity risks, management’s role in assessing and managing such risks, and the Board of Directors’ oversight of cybersecurity risks. Companies also must disclose in a Form 8-K the nature, scope and timing of any material cybersecurity incidents identified and the material impact or reasonably likely material impact on the company. We expect to face increased costs to comply with this new SEC cybersecurity rule, including increased costs for cybersecurity training and management. Furthermore, the requirement to report cybersecurity incidents within such a short time frame could mean that there will not be sufficient time to halt a breach before having to report it, potentially giving hackers an advantage.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Use of Proceeds from Registered Securities
None.
ITEM 5. AMENDMENT AND RESTATEMENT OF BYLAW
49
Effective as of September 26, 2023, pursuant to the power granted by the certificate of incorporation as permitted by the Delaware General Corporation Law (the “DGCL”), the board of directors (the “Board”) of The Joint Corp., a Delaware corporation (the “Company”), approved the amendment and restatement of the Company’s Third Amended and Restated Bylaws pursuant to the Fourth Amended and Restated By-Laws attached hereto and incorporated herein by reference as Exhibit 3.2 (the “New Bylaws”), effective as of September 26, 2023. The following is a summary of the material amendments to the Company’s Third Amended and Restated Bylaws effected by the New Bylaws:

•amend certain provisions to align them with and conform them to amendments to the DGCL that have been effected since the Third Company’s Amended and Restated Bylaws were last materially amended, including, without limitation, to:

•clarify that the Company may hold meetings of its stockholders by means of remote communications as permitted by Section 211 of the DGCL;

•align the requirements for the list of stockholders entitled to vote at a meeting of stockholders to Section 219 of the DGCL;

•align the provisions governing the fixing of the record date or dates for determining stockholders entitled to receive notice of or to vote at a meeting of stockholders or any adjournment thereof to Section 213 of the DGCL;

•align the provisions governing the creation of committees of the Board to Section 141(c)(2) of the DGCL;

•align the provisions governing director resignations to Section 141of the DGCL;

•align the provisions governing certificated and uncertificated shares to Section 158 of the DGCL;

•align the provisions governing lost stock certificates to Section 167 of the DGCL;

•align the requirements for waivers of notice of meetings of the Board and stockholders to Section 229 of the DGCL; and

•permit stockholder action by consent in lieu of a meeting to be take by “electronic transmission” in addition to “writing” as permitted by the DGCL;

•clarify the ability of the person presiding over a meeting of the Company’s stockholders to prescribe rules and regulations for the conduct of such meeting;

•include a “forum selection” clause to require (i) Delaware corporate law related claims to be adjudicated by the Delaware Court of Chancery as permitted by Section 115 of the DGCL and (ii) actions asserting a cause of action under the Securities Act of 1933, as amended, to be adjudicated by the federal district court in the State of Delaware;

•conform the provisions governing the calling of special meetings of stockholders to the Company’s certificate of incorporation;

•reduce the stockholder vote required for business (other than nominations for election of directors and where a higher vote is required by applicable law or the Company’s certificate of incorporation or bylaws) to a majority of the votes cast at a meeting at which a quorum is present;

•amend the provisions governing procedural and notice requirements for stockholders proposing to nominate individuals for election as directors or propose other business to be conducted (other than proposals to be included in the Company’s proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended) at annual meetings of stockholders or to nominate individuals for election as directors at special meetings of stockholders at which one or more directors are to be elected pursuant to the Company’s notice of such meeting, including, without limitation, to:

•modify the deadlines for (i) stockholder nominations of individuals for election as directors at any annual meeting of stockholders or any special meeting of stockholders at which one or more directors are to be elected pursuant to the Company’s notice of such meeting or (ii) stockholder proposals of other business to be conducted at any annual meeting of stockholders, in each case, to align with the deadlines that are most prevalent among public companies;

•modify the notice requirements for stockholder nominations of individuals for election as directors to align with Rule 14a-19 (i.e., the “universal proxy card rules”);

50
•modify the notice requirements for stockholder nominations of individuals for election as directors and stockholder proposals of other business to require notification of intent to solicit proxies or deliver a proxy statement; and

•clarify that a failure to comply with such notice and procedural requirements, including failing to appear at the meeting to present such nomination or business, will result in a stockholder’s nomination or proposal of other business being disregarded;

•amend the provisions governing the Board to:

•permit solely the Board to fill vacancies and newly created directorships on the Board (consistent with the Company’s certificate of incorporation); and

•revise the quorum requirements for Board meetings to be based on voting power (rather than number) of directors;

•amend the provisions governing meetings of stockholders to clarify that annual stockholders may be postponed by action of the Board at any time in advance of such meetings and that special meetings of stockholders may be postponed by action of the Board or by the person calling such meeting (if other than the Board) at any time in advance of such meeting; and

•amend the indemnification provisions to mandate future indemnification of litigation expenses solely for directors and officers (not also employees and agents).
The foregoing description of the amendments effected by the New Bylaws is qualified in its entirety by the full text of the New Bylaws attached hereto and incorporated herein by reference as Exhibit 3.2.
ITEM 6. EXHIBITS

51
Table of Contents
EXHIBIT INDEX
Exhibit
Number		Description of Document
3.1
3.2*
10.1
31.1*
31.2*
32**
101.INSXBRL Instance Document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith
** Furnished herewith, not filed
52
THE JOINT CORP.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

THE JOINT CORP.
Dated: September 26, 2023By:/s/ Peter D. Holt
Peter D. Holt
President and Chief Executive Officer
(Principal Executive Officer)
Dated: September 26, 2023By:/s/ Jake Singleton
Jake Singleton
Chief Financial Officer
(Principal Financial Officer)

53

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

© 2025 CompaniesMarketcap.com